2013 faseb science research conferences advisory …...6. providing a final conference agenda. the...
TRANSCRIPT
Proposal #: 15-25
2013 FASEB SCIENCE RESEARCH CONFERENCES ADVISORY COMMITTEE MEETING
TOPIC FOR CONSIDERATION TOPIC NAME: LYSOPHOSPHOLIPIDS AND RELATED MEDIATORS – FROM BENCH TO CLINIC PREVIOUS TITLE: Lysophospholipids and Other Related Mediators – From Bench to Clinic SUBMITTED BY: David Brindley, University of Alberta Denise Hemmings, University of Alberta
Susan Pyne, University of Strathclyde Nigel Pyne, University of Strathclyde
YEAR REQUESTED FOR
SCHEDULING: 2015
SITE REQUESTS: 1. Banff Conference Center, Banff, Alberta, Canada DATE REQUESTS: 1. August 23-28, 2015
2. September 13-18, 2015 3. June 21-26, 2015
YEAR(S) CONFERENCE
HAS BEEN HELD: 2001, 2003, 2005, 2007, 2009, 2011, 2013
NOTES: To the best of our knowledge, there is not a direct conflict with any other
FASEB SRC or other society or industry meeting.
2
FASEB SRC Proposal Instructions Attached are the instructions and requirements for submitting a FASEB SRC proposal. Please complete sections 1-6 before submitting your information. Please submit your proposal by September 23, 2013. Your proposal will be reviewed by the FASEB Science Research Conference Advisory Committee in early November. Once your Conference is approved you will be assigned a Conference manager from the FASEB SRC Team who will provide you with detailed instructions on program management and timelines to help make your planning process successful and seamless.
Section 1: Organizer Responsibilities: By submitting a FASEB Science Research Conference proposal for consideration by the FASEB SRC Advisory Committee, the organizer (s) accepts the responsibility for producing a successful Conference. Such responsibilities include:
1. Anything related to the scientific portion of your Conference. You will need to provide the Conference title and topics. The Conference title and topics should be timely and attractive. 2. Attendance to your Conference is expected to be no less than 100 participants. 3. Contacting all speakers and session chairs to invite and confirm their participation. Speakers should be informed that their expenses will be reimbursed after the Conference and only to the extent that funds are available. We recommend you do not commitment to a speaker a specific amount of funds prior to the Conference. (Note: Invited speakers and session chairs are required to remain at the Conference for a minimum of three full days and three full nights in order to be eligible for reimbursement of any Conference related expenses.)
4. Reviewing and approving the submitted attendees.
5. Including a “Meet the Expert” session in your program. This session is aimed at encouraging the younger investigators an opportunity to network with the more established and senior PIs in your field. 6. Providing a final Conference agenda. The program will include the speaker abstracts (in presentation order), poster abstracts, and a poster listing of the submitted abstracts. The Conference Manager will prepare the cover for the program, the participant list and have the final packet of materials reproduced and shipped to the venue. 7. Constant communication with your Conference Manager. By doing so, this will eliminate any miscommunication or understanding of the policies and procedures that will needed to be followed.
3
Section 2: Conference Title & Organizer Information: Please insert the title of the Conference as you would like it to be advertised in future publications. List the organizing committee below and complete contact information and attach a brief CVs (maximum 3 pages) in NIH format for each. TITLE OF CONFERENCE: Lysophospholipids and related mediators-from bench to clinic. # of EXPECTED ATTENDEES: 130-200 Preferred Primary Point of Contact for Proposal Questions: Name: David Brindley Full Address: Department of Biochemistry, University of Alberta, 357 Heritage Medical Research Centre, Edmonton, Alberta, T6G 2S2, Canada Telephone #: 780-492-2078 Email Address: [email protected] Science Categories (select up to 3)
1) Signaling by lysophosphidate and translation to clinical practice 2) Signaling by sphingosine 1-phosphate and translation to clinical practice 3) New technologies for lysolipid mediators
(see Attachment A - for marketing and audience generation purposes) Organizing Committee: Organizer Chair: David Brindley Title: Dr. Affiliation: University of Alberta Full Address: Department of Biochemistry, 357 Heritage Medical Research Centre, Edmonton, Alberta, T6G 2S2, Canada Phone: 780-492-2078 Email: [email protected] Organizer Co-Chair: Denise Hemmings Title: Dr Affiliation: University of Alberta Full Address: Department of Obstetrics and Gynecology, and Medical Microbiology and Immunology, 227 Heritage Medical Research Centre, Edmonton, Alberta, T6G 2S2, Canada Phone: 780-492-2098 Email: [email protected] Committee member: Susan Pyne Title: Prof Affiliation: University of Strathclyde Full Address: Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK ___________________________________________________________________________ Phone: +44(0)141 548 2012 Email: [email protected]
4
Committee member: Nigel Pyne Title: Prof Affiliation: University of Strathclyde Full Address: Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK ___________________________________________________________________________ Phone: +44(0)141 548 2659 Email: [email protected] Other Committee member to be appointed: Title: ____________________ Affiliation: ___________________________________________________________________ Full Address: ________________________________________________________________ ___________________________________________________________________________ Phone: _______________________ Email: ________________________________________ Committee member: Title: ____________________ Affiliation: ___________________________________________________________________ Full Address: ________________________________________________________________ ___________________________________________________________________________ Phone: _______________________ Email: ________________________________________
Section 3: Program Submission Requirements & Outline:
Please insert program details in day order as requested below. Session titles should be listed with session chairs and affiliations. Indicate the proposed tentative talk titles within each session and list up to at least 4 speakers per session (not including short talks selected from submitted abstracts). Please remember to also include the required “Meet the Expert” session. The FASEB SRC Advisory Committee requires all session chairs to be confirmed before the submission of the application. Be sure to indicate with a "C" if the session chair is confirmed, indicate with a “CS” if the speaker is confirmed, indicate with a "W" which session chairs and speakers are women, indicate with an "M" which session chairs and speakers are of a minority group and indicate with the word “NEW” which session chairs and speakers are new to the program. (Note: The committee defines new speakers as one that has NOT spoken at the last two (2) Conferences.) Overview of Program Flow # of Days: 6, from Sunday evening to Friday noon # of Sessions per day: 2: Morning and evening sessions are for 3h (3 x 30 min
plus 30 min break 3 x 20 min). # of Speaker per day: 6 invited, 2 have been reserved and will be chosen from
literature in 2013/14 to identify new and younger speakers. Four speakers will be chosen from trainees who submit posters.
# of Session chairs per day: 4 with 2 chairs and 2 co-chairs # of Breakouts per day: 2 # of Abstracts per day: At least 30
5
Proposed Program: Lysophospholipids and related mediators-from bench to clinic. This is a well-established conference where we have developed a very successful program outline every two years since 1999. We have a devoted list of regular attendees and will have no trouble recruiting Chairs and Speakers. Day 1: Sunday pm, August 23, 2015 Title of Session: Session 1. Plenary Session Session Chair & Affiliation (C): Welcoming remarks, Dr. David Brindley, University of Alberta Keynote speaker 1: (W) Lina Obeid Affiliation: Stony Brook School of Medicine Tentative title: Regulation of cancer cell invasion by sphingolipids. Keynote speaker 2: (W) Susan Smyth Affiliation: University of Kentucky Tentative title: Autotaxin and lysophosphatidate in the control of vascular responses. Day 2 Monday am, August 24, 2015 Title of Session: Session 2: Metabolism and receptors: Fundamental aspects of lysophospholipid signaling (1) Session Chair & Affiliation: Andrew Morris, University of Kentucky Co-chair & Affiliation. (C) David Brindley, University of Alberta Speaker 1: Woulter Moolenaar Affiliation: The Netherlands Cancer Institute Tentative Title of Talk: Autotaxin, tumor progression and metastasis. Speaker 2: Olivier Peyruchaud Affiliation: INSERM Unit 1013, Lyon, France Tentative Title of Talk: Regulation of bone metastasis by autotaxin Speaker 3: (NEW) (M) Junken Aoki Affiliation: Tohoku University, Sendai, Japan. Tentative Title of Talk: Regulation of cell signaling through lysophosphatidate receptors. Group photograph and FASEB sponsored coffee break Speaker 4: Chosen from the literature based on a recent significant publication Affiliation: N/A Tentative Title of Talk: N/A Speaker 5: A young investigator chosen from submitted poster abstracts Affiliation: N/A Tentative Title of Talk: N/A
6
Speaker 6: A young investigator chosen from submitted poster abstracts Affiliation: N/A Tentative Title of Talk: N/A Lunch Poster session 1 Meet the expert session 1 Dinner Title of Session: Session 3: Metabolism and receptors: Fundamental aspects of lysophospholipid signaling (2) Session Chair & Affiliation: Olivier Peyruchaud, INSERM Unit 1013, Lyon, France Co-chair & Affiliation. Nigel Pyne (C), University of Strathclyde, UK Speaker 2: Andrew Morris Affiliation: University of Kentucky Tentative Title of Talk: Role of lipid phosphate phosphatases and related proteins in regulating cell signaling. Speaker 2: (W) (NEW) Ruth Lehmann Affiliation: Howard Hughes Medical Institute, New York Tentative Title of Talk: Role of Wunen protein in morphogenesis Speaker 3: (NEW) Jean-Sabastian Saulnier-Blache Affiliation: UMR1048, Université de Toulouse, France Tentative Title of Talk: Role of autotaxin and lysophosphatidate in adipose tissue FASEB sponsored coffee break Speaker 4: Chosen from the literature based on a recent significant publication Affiliation: N/A Tentative Title of Talk: N/A Speaker 5: A young investigator chosen from submitted poster abstracts Affiliation: N/A Tentative Title of Talk: N/A Speaker 6: A young investigator chosen from submitted poster abstracts Affiliation: N/A Tentative Title of Talk: N/A Day 3 Tuesday am, August 25, 2015 Title of Session: Session 4: Fundamental aspects of sphingosine 1-phosphate signaling (1)
7
Session Chair & Affiliation: (W) Sarah Spiegel, Virginia Commonwealth University Co-chair & Affiliation. (W) Julie Saba, Children’s Hospital Oakland Research Institute. Speaker 1: (W) Sarah Spiegel Affiliation: Virginia Commonwealth University Tentative Title of Talk: Role of sphingosine kinases in cell signaling Speaker 2: (W) Julie Saba Affiliation: Children’s Hospital Oakland Research Institute Tentative Title of Talk: Sphingosine 1-phosphate lyase as a modulator of sphingosine 1-phosphate signaling Speaker 3: (W) (NEW) Dagmar Meyer Zu Heringdorf Affiliation: Klinikum der Johann Wolfgang Goethe-Universität, Frankfurt am Main, Germany Tentative Title of Talk: Pharmacology of sphingosine 1-phosphate signaling. FASEB sponsored coffee break Speaker 4: Chosen from the literature based on a recent significant publication Affiliation: N/A Tentative Title of Talk: N/A Speaker 5: A young investigator chosen from submitted poster abstracts Affiliation: N/A Tentative Title of Talk: N/A Speaker 6: A young investigator chosen from submitted poster abstracts Affiliation: N/A Tentative Title of Talk: N/A Lunch Free afternoon Poster session 1 continued Dinner Title of Session: Session 5: Fundamental aspects of sphingosine 1-phosphate signaling in cancer (2) Session Chair & Affiliation: Stuart Pitson (NEW), University of Adelaide, Australia Co-chair & Affiliation. (C) (W) Susan Pyne, University of Strathclyde, UK Speaker 1: (NEW) Stuart Pitson Affiliation: University of Adelaide, Australia Tentative Title of Talk: Sphingosine kinases, iron metabolism and cancer. Speaker 2: (W) (CS) Susan Pyne,
8
Affiliation: University of Strathclyde, UK. Tentative Title of Talk: Sphingosine 1-phosphate and cancer Speaker 3: (NEW) Besim Ogretman Affiliation: Medical University of South Carolina Tentative Title of Talk: Sphingosine 1-phosphate and chemoresistance FASEB sponsored coffee break Speaker 4: Chosen from the literature based on a recent significant publication Affiliation: N/A Tentative Title of Talk: N/A Speaker 5: A young investigator chosen from submitted poster abstracts Affiliation: N/A Tentative Title of Talk: N/A Speaker 6: A young investigator chosen from submitted poster abstracts Affiliation: N/A Tentative Title of Talk: N/A Day 4 Wednesday, August 26, 2015 Title of Session: Session 6: Fundamental aspects of lysophospholipid signaling in neurobiology. Session Chair & Affiliation: (M) Jerold Chun, Scripps, Research Institute Co-chair & Affiliation. (M) Hiroshi Ueda, Nagasaki University, Japan Speaker 1: (M) Jerold Chun Affiliation: Scripps, Research Institute Tentative Title of Talk: Lysophosphatidate and the central nervous system Speaker 2: (M) Hiroshi Ueda Affiliation: Nagasaki University School of Biomedical Science, Japan Tentative Title of Talk: Lysophosphatidate and pain. Speaker 3: (W) (NEW) Anja Braeuer Affiliation: Universitaetsmedizin Charité, Berlin, Germany Tentative Title of Talk: Lysophosphatidate and neural plasticity FASEB sponsored coffee break Speaker 4: Chosen from the literature based on a recent significant publication Affiliation: N/A Tentative Title of Talk: N/A Speaker 5: A young investigator chosen from submitted poster abstracts
9
Affiliation: N/A Tentative Title of Talk: N/A Speaker 6: A young investigator chosen from submitted poster abstracts Affiliation: N/A Tentative Title of Talk: N/A Lunch Poster session 2 Meet the expert session 2 Dinner Title of Session: Session 7: Lysolipid mediators in the pathophysiology of vascular function Session Chair & Affiliation: (W) Susan Smyth, University of Kentucky Session Co-Chair & Affiliation: (C) (W) Denise Hemmings, University of Alberta Speaker 1: (M) Timothy Hla Affiliation: Cornell University, New York Tentative Title of Talk: Sphingosine 1-phosphate and the vasculature Speaker 2: (W) (CS) Denise Hemmings Affiliation: University of Alberta, Edmonton, Canada Tentative Title of Talk: Sphingosine 1-phosphate and the control of vascular tone Speaker 3: Nigel Pyne (CS) Affiliation: University of Strathclyde, UK Tentative Title of Talk: Hypoxia, sphingosine kinase and pulmonary hypertension FASEB sponsored coffee break Speaker 4: Chosen from the literature based on a recent significant publication Affiliation: N/A Tentative Title of Talk: N/A Speaker 5: A young investigator chosen from submitted poster abstracts Affiliation: N/A Tentative Title of Talk: N/A Speaker 6: A young investigator chosen from submitted poster abstracts Affiliation: N/A Tentative Title of Talk: N/A Day 5 Thursday, August 27, 2015 Title of Session: Session 8: Lysolipid mediators in immunity and inflammation Session Chair & Affiliation: (M) Timothy Hla, Cornell University
10
Session Co-Chair & Affiliation: Jason Cyster, University of California, San Francisco. Speaker 1: Jason Cyster Affiliation: University of California, San Francisco Tentative Title of Talk: Affiliation: University of California, San Francisco Tentative Title of Talk: Sphingosine 1-phosphate and the regulation of lymphocyte function. Speaker 2: (W) Andrea Huwiler Affiliation: University of Bern, Switzerland Tentative Title of Talk: Sphingosine 1-phosphate and fibrosis. Speaker 3: (N) (M) Viswanathan Natarajan Affiliation: University of Illinois at Chicago Tentative Title of Talk: Lysophospholipds in inflammatory lung disease FASEB sponsored coffee break Speaker 4: Chosen from the literature based on a recent significant publication Affiliation: N/A Tentative Title of Talk: N/A Speaker 5: A young investigator chosen from submitted poster abstracts Affiliation: N/A Tentative Title of Talk: N/A Speaker 6: A young investigator chosen from submitted poster abstracts Affiliation: N/A Tentative Title of Talk: N/A
Lunch Poster session 2 continued Dinner Title of Session: Session 9: Lysophospholipids in bone and muscle development Session Chair & Affiliation: (W) Ruth Lehmann, Howard Hughes Medical Institute, New York (C) Co-chair & Affiliation: (W) Paola Bruni, University of Floerence, Italy Speaker 1: Jeffrey Dixon Affiliation: University of Western Ontario, Canada Tentative Title of Talk: Lysophosphatidate and signaling in bone Speaker 2: (M) Masaru Ishii Affiliation: Osaka University School of Medicine Tentative Title of Talk: Sphingosine 1-phosphate and bone development
11
Speaker 3: (W) Paola Bruni Affiliation: University of Florence, Italy Tentative Title of Talk: Sphingosine 1-phosphate in myoblast differentiation FASEB sponsored coffee break Speaker 4: Chosen from the literature based on a recent significant publication Affiliation: N/A Tentative Title of Talk: N/A Speaker 5: A young investigator chosen from submitted poster abstracts Affiliation: N/A Tentative Title of Talk: N/A Speaker 6: A young investigator chosen from submitted poster abstracts Affiliation: N/A Tentative Title of Talk: N/A
Day 6 Friday, August 28, 2015 Title of Session: Session 10: Therapeutics and new technologies for lysolipid mediators Session Chair & Affiliation: Gabor Tigyi, University of Tennessee (C) Co-chair & Affiliation: Roger Sabbaddini, Lpath Inc., San Diego. Speaker 1: Gabor Tigyi Affiliation: University of Memphis Tentative Title of Talk: Lysophosphatidate therapeutics Speaker 2: Roger Sabbaddini Affiliation: Lpath Inc., San Diego. Tentative Title of Talk: Lysophosphatidate and sphingosine 1-phosphate antibodies in therapeutics. Speaker 3: Kevin Lynch Affiliation: University of Virginia Tentative Title of Talk: Pharmacological regulation of sphingosine kinase and sphingosine 1-phosphate receptors FASEB sponsored coffee break Speaker 4: Chosen from the literature based on a recent significant publication Affiliation: N/A Tentative Title of Talk: N/A Speaker 5: A young investigator chosen from submitted poster abstracts Affiliation: N/A Tentative Title of Talk: N/A Speaker 6: A young investigator chosen from submitted poster abstracts
12
Affiliation: N/A Tentative Title of Talk: N/A
End of Conference
Boxed Lunches
13
Section 4: Content Assessment: Please complete the grid below which will assist the FASEB SRC Advisory Committee in assessing the requirements of the proposal. Positive reviews are given to proposals with confirmation of session chairs and invited speakers, new speakers to the program, a good representation of women, and a sufficient number of short talks from junior level investigators. Indicate the number of session chairs that have confirmed their participation: 4 Indicated the number of women included with the entire program: so far 11 Indicate the number of session chairs/speakers of a minority group: 6 Indicate the number of “new” speakers to the Conference: plus selected speakers from literature in 2013/2015 and trainees from selected posters.
7
Indicate the number of speakers that have confirmed their participation in the Conference : most not yet invited
3
Indicated the number of talks set aside for junior level investigators to present their work: 27 Indicated the number of poster sessions that will be organized: at least 2 Please provide a brief description of the how the poster sessions will be organized: There will be two poster sessions, which will be left for viewing and discussion for two days each. We will arrange a Panel of judges to award prizes to the best posters. The presenters of the most exciting posters will be selected in advance for oral presentations Indicate (if known) if there is a potential of a conflict with any other FASEB SRC or any other society or industry meeting. If yes, please explain the conflict in detail. We know of no other conflicting conference from FASEB at this stage, which is two years in advance.
14
Section 5: Scheduling & Location Preferences:
Select three (3) choices of dates that you wish to hold the Conference. Define the pattern flow, start date, and end date of your Conference Week 1: August 23-28, 2015, The Banff Conference Centre is holding these dates for the meeting. The Sunday evening is for registration and presentation of two Keynote speakers. Friday will be a half day finishing at noon. Week 2: September 13-18, 2015 Week 3: June 21-26, 2015 Select at least three (3) cities/venues for consideration. Venue #1 should be the most preferred. (Note: We will do our best to give you your first choice but it cannot be guaranteed.) Please circle the type of facility you would like to host the program. Conference Center: The Banff Conference Centre in the Banff National Park in the Canadian Rockies is an ideal venue and accommodation is already reserved for August 23-28, 2015.
Cities/venues Preference Banff Conference Centre, Banff, Alberta, Canada
1
1 2 3 1 2 3
Contingent upon interest. Every effort will be given to the Organizer’s choice of venue and date choice. Due to limited availability and scheduling site and date preferences are not guaranteed. For each conference year, A minimum of 4 conference proposals must have interest in a potential venue in order for that venue to be used as a conference location. Section 6: Justification:
The SRC Advisory Committee requires all proposals to include answers to the following eleven (11) questions. In a separate Microsoft word document, answer each individual question accordingly. Once completed, name the document the title of your Conference and attach this file to your email when submitting the final proposal. 1. Explain why this topic is of high current interest to the scientific community. 2. Is this a rapidly growing field? 3. Has there been previous Conferences of this topic? If so, where and when were the Conferences held? How many participants attended? (Additionally, consider whether or not another similar Conference /meeting is scheduled that might cause a conflict).
15
4. How many participants do you expect to attend the Conference? 5. What is the percentage of women have participated in this Conference in the past (if it has been previously held)? 6. How will you recruit young investigators to attend and participate in the Conference? 7. How will you recruit and select new speakers? 8. Who will attend the Conference? (Provide specifics). 9. Where will the Conference be advertised? What types of media will be used to advertise your Conference? (Provide specifics).
Section 7: Submitting Your Proposal: Please read the directions below for submitting your proposal. Feel free to contact the SRC Office should you have any questions or need guidance in submitting your proposal. Instructions for submitting your proposal: 1. Print or save a copy of this form for your own records. 2. Click the "Submit By Email" button below. In the pop-up box, select the option that best describes how you send email. 3. Enter the title of your Conference in the message line. 4. Attach the following items to your e-mail:
• The file saved to your personal computer with the answers to the eleven questions in Section 6: Justification
• CVs (in NIH Format) for all Organizers and Co-Organizers (maximum of 3 pages). 5. After you have completed the steps above, click “Submit by Email” button to send your proposal.
Thank you in advance for your proposal submission! We look forward to helping you plan a successful Conference.
For more information, please contact: Marcella Jackson, Director, Office of Meetings and Conferences 301-634-7012, [email protected] Robin Crawford, Conference Manager FASEB Science Research Conferences 301-634-7093, [email protected]
Section 6: Justification:
1. Explain why this topic is of high current interest to the scientific community. Work in this area of cell signaling by lipid mediators including lipid phosphates is growing in intensity and importance. There has been immense progress in the last 20 years and we are now seeing that the knowledge gained in this field of research is increasingly being applied to developing new therapeutic approaches to treating a large variety of human diseases and novel prognostic biomarkers. One therapeutic example is the use of FTY720 (GilenyaTM), which is phosphorylated to a sphingosine 1-phosphate mimetic, an immuno-modulator in the treatment of multiple sclerosis. Regulating signaling by lysophosphatidate and sphingosine 1-phosphate is now being translated into the treatment of fibrosis and cancer (inhibitors and humanized antibodies). Papers in this area are published regularly in high profile journals such as Nature, Cancer Cell, Science, PNAS etc.
2. Is this a rapidly growing field?
Yes, very much so from the discovery science perspective through to the translation of the findings into clinical practice as described above. For LPA, the average is 225 papers/year for 2008-2012 and 285 papers to date in 2013. For S1P, the average is 242 papers/year for 2008-2012 and 266 papers to date in 2013, thereby demonstrating current growth in the field.
3. Has there been previous Conferences of this topic? If so, where and when
were the Conferences held? How many participants attended? (Additionally, consider whether or not another similar Conference /meeting is scheduled that might cause a conflict). This conference began at the New York Academy of Sciences in 1999 and it became a FASEB Conference in 2001. The Conference has been held successfully every two years since then in a variety of locations. The number of participants at each conference has exceeded 130 and we believe that the response from attendees has been uniformly positive and enthusiastic. We are not aware of conflicting programs.
4. How many participants do you expect to attend the Conference?
We expect between 130-200 participants. There was considerable enthusiasm at the business meeting at the 2013 FASEB conference held in Niseko, Japan to hold another conference and especially to hold it in the Canadian Rockies. We have an excellent and attractive venue at the Banff Conference Centre, which is reserved, and expect a higher than normal turnout.
5. What is the percentage of women have participated in this Conference in
the past (if it has been previously held)?
Approximately 20%. We will make every effort to increase this to a level closer to parity in gender. The organizing committee this year consists of two men and two women. We may extend this committee and we will actively seek to increase the number of women both attending and involved as speakers. The present proposed program contains 11 female speakers out of 29 speakers or about 38%. We have, therefore, essentially doubled the participation of female speakers compared to the last meeting.
6. How will you recruit young investigators to attend and participate in the
Conference? We will advertise the meeting widely and encourage principal investigators to bring their trainees. We will indicate that we will reserve a large proportion of the oral presentations for selection from abstract submissions and include as many young investigators as possible in the program. We will also award poster prizes to encourage trainees. We will actively seek additional funding to subsidize travel costs for all young investigators.
7. How will you recruit and select new speakers? We have developed a draft program that includes leaders in the field and investigators relatively new to the field but who are making significant contributions. We have left one space in each section open to enable us to follow the literature in this rapidly moving area and select the new speakers on the basis of exciting achievements and progress that will occur closer to the 2015 dates. This has minimized the automatic selection of established investigators and it will introduce new, younger and female speakers into the program.
8. Who will attend the Conference? (Provide specifics).
We have built up a large number of devoted attendees who consider this to be the most important conference in this area of research. We, therefore, expect to attract the majority of attendees from research teams who are working in this area. Also, we are attracting an increasing number of participants from the pharmaceutical industry who are looking for the translation of the discovery research into clinical practice.
9. Where will the Conference be advertised? What types of media will be
used to advertise your Conference? (Provide specifics). The conference will be advertised through: a) the FASEB website; b) Emails to attendees of previous conferences; c) targeted announcements through professional societies, journals and other relevant conferences.
10. From what sources and resources will you use to solicit funds for the Conference? (Provide specifics?). We will reapply to sponsors who generously supported us in past meetings. These include: Amino Up Chemical Co. Ltd., Avanti Polar Lipids, Earth Chemical
Co. Ltd., Echelon Biosciences, Food Chemicals, Hamanaka Dermato Logical Clinic, Kao, Lpath Inc, LS Research Committee, Mitsubishi Tanabe Pharma Corp, Nissei Bio, Ono Pharmaceuticals Co. Shionogi & Co. Ltd, Taisho Pharmaceutical Co., Unitika, Université Laval, Journal of Lipid Research, Biochemical Journal and NIH. In addition, we will apply to Alberta Innovates-Heath Solutions, Canadian Institutes of Health Research and the University of Alberta for funding.
11. What societies and disciplines will you attract to attend the conference? (Provide specifics) We expect to attract a wide range of biological scientists including biochemists, cell biologists, physiologists and pharmacologists from The American Physiological Society, American Society for Biochemistry and Molecular Biology, American Society for Pharmacology and Experimental Therapeutics, American Association of Immunologists, Society for Developmental Biology and the equivalent Canadian, European, Japanese, Chinese, Korean and Australian Societies.
12. Are you planning on submitting a similar application to another
organization for additional funding and sponsorship? If yes, please clarify. Our preference is to continue to organize this established meeting with FASEB. At present, we have no plans to apply to another organization for sponsorship other than the agencies listed above to which we will apply for funding.
Page 1
BIOGRAPHICAL SKETCH
NAME David N. Brindley
POSITION TITLE Professor of Biochemistry, University of Alberta
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable.)
INSTITUTION AND LOCATION DEGREE (if applicable) MM/YY FIELD OF STUDY
University of Birmingham, Birmingham, England B.Sc. First class 1963 Medical Biochemistry University of Birmingham, Birmingham, England Ph.D. 1966 Medical Biochemistry University of Birmingham, Birmingham, England D.Sc. 1977 Biochemistry
A. Employment 1963 – 1966 MRC Research Student in Medical Biochemistry with G. Hübscher, U of Birmingham, U.K. 1966 – 1967 NIH Research Fellow with Professor K. Bloch in Chemistry, Harvard University, Mass., U.S.A. 1969 – 1976 Appointed as Lecturer in Biochemistry, University of Nottingham, U.K. 1976 – 1979 Senior Lecturer in Biochemistry, University of Nottingham, U.K. 1979 – 1985 Reader in Biochemistry, University of Nottingham, U.K. 1985 – 1987 Personal Chair as Prof. of Metabolic Control in Biochemistry, University of Nottingham, U.K. 1988 – present Professor of Biochemistry, U of Alberta, Edmonton, Canada. 2000 – present Director, Signal Transduction Research Group, University of Alberta B. Professional Activities 1976 Chairman of Lipid Group of the Biochemical Society 1973 – 1975 Editorial Board of Steroids and Lipid Research 1977 – 1984 Editorial Board of Biochemical Journal and Deputy Chairman from 1982-84. 1980 – 1998 Advisory Board of Editors for British Journal on Alcohol and Alcoholism 1984 – 1996 Editorial Advisory Board of Biochemical Pharmacology 1985 – 1987 Member of Systems Board Grants Committee B for British Medical Research Council 1986 – 1987 Committee Member of British Biochemical Society 1988 – 1991 Member of Canadian Heart Foundation, Junior Personnel Committee 1990 – 1992 Member of Studentships Committee for Alberta Heritage Foundation for Medical Research 1991 - 1993 Long-term planning Committee of Canadian Atherosclerosis Society 1991 – 1995 Member of National Grants Committee for Canadian Diabetes Association 1991 – 2007 Editorial Advisor for Biochemical Journal 1992 – 1995 Section Editor for Obesity Research 1993 – 1997 Editor for International Journal of Obesity 1994 Organizing Committee 7th International Congress on Obesity 1995–1999 MRC Canada Cell Physiology Grants Committee 1995–2005 Corresponding member to Comm. of Intl. Conf. On the Bioscience of Lipids 1995–1999 Member Cell Physiology Grants Committee, CIHR 1996–2004 Grants Award Committee, Heart & Stroke Foundation of Alberta 2000–2002 Investigators Awards Committee, Canadian Institutes for Health Research 1999–2001 Vice President, Obesity Canada 1999–2003 Editorial Board of Biochemical Journal and Deputy Chairman from 2000-2003 2004 National Organizing Committee (Secondary Messengers and Phosphoproteins; Montréal) 2000– Grant reviews NIH and allied agencies. 2005–2006 Organizing Committee 2nd ISN Neurochem Conf. on Neural Glycomics and Lipidomics 2006–2012 CIHR Committee for cardiovascular complications of diabetes 2008–2011 Canadian Cancer Society Research Institute Grants Committtee 2008–present AHFMR Fellowships Awards Committee 2011–present Fellowships Committee of Heart and Stroke Foundation of Canada
Page 2
C. Honors 1963 1st Class Honors B.Sc., Medical Biochemistry, University of Birmingham, UK 1963-1967 Medical Research Council Studentship and Postdoctoral Fellowship 1985-1987 Personal Chair of Metabolic Control, University of Nottingham 1988 – 2009 Alberta Heritage Foundation for Medical Research Medical Scientist, Renewed 4 times 1988-present Academico Correspondiente of the Royal Academy of Pharmacy, Spain 1995 Fournier Pharma-CLC Award in Atherosclerosis Research Communication 2009 – 2011 AHFMR Senior Investigator 2010 Elected Fellow of the Royal Society of Canada C. Peer Reviewed Articles 2008-2013 (from 197 total) 170. The potential role for dietary long chain polyunsaturated N-3 fatty acids during chemotherapy treatment.
PD. Biondo, DN. Brindley, MD. Sawyer and CJ. Field. J. Nutr. Biochem. 19 (2008), 787-796. IF = 4.26. 171. Glucocorticoids and cAMP selectively increase hepatic lipin-1 expression and insulin acts
antagonistically. B Manmontri, M Sariahmetoglu, MB Khalil, M Sundaram, Z Yao, K Reue, R Lehner and DN Brindley, J Lipid Res. 49 (2008) 1056-1067. IF = 5.59
172. Protein Kinase C-ε Regulates Sphingosine 1-Phosphate-Mediated Migration of Human Lung Endothelial Cells through Activation of Phospholipase D2, Protein Kinase C-ζ, and Rac1. I Gorshkova, D He, E Berdyshev, P Usatuyk, M Burns, S Kalari, S Pendyala, JGN. Garcia, NJ Pyne, DN Brindley and V. Natarajan. J Biol Chem. 283 (2008) 11794-11806. IF = 5.12
173. Regulation of lipin-1 gene expression by glucocorticoids during adipogenesis. P Zhang, L O’Laughlin, DN Brindley, and K Reue, J. Lipid Res. 49 (2008) 1519-1528. IF = 5.59
174. Multiple Roles for Lipins/Phosphatidate Phosphatases in Lipid Metabolism. K. Reue and DN Brindley, J. Lipid Res. 49 (2008) 2493-2503. IF = 5.59
175. Scheduled feeding-mediated changes in metabolism: stress response and pathophysiology in insulin resistant, atherosclerosis-prone JCR:LA-cp rats JC Russell, SD Proctor, SE Kelly, and DN Brindley Am. J. Physiol. 294 (2008) E1078-1087. IF = 4.75
176. The level and compartmentalization of phosphatidate phosphatase-1 (lipin-1) control the assembly and secretion of hepatic very low density lipoproteins. M Bou Khalil, M Sundaram, H-Y Zhang, PH Links, JF Raven, B Manmontri, M Sariahmetoglu, K Tran, K Reue, DN Brindley and Z Yao. J. Lipid Res. 50 (2009) 47-58. IF = 5.59
177. Autotaxin protects MCF-7 breast cancer and MDA-MB-435 melanoma cells against Taxol-induced apoptosis. N Samadi, C Gaetano, IS Goping and DN Brindley. Oncogene 28 (2009) 1028-1039. IF=6.89.
178. Inhibition of autotaxin production or activity blocks lysophosphatidylcholine-induced migration of human breast cancer and melanoma cells. CG Gaetano, N Samadi, JL. Tomsig, TL Macdonald, KR Lynch and DN Brindley. Mol Carcinogenesis 40 (2009) 1185-1194. IF = 3.09.
179. Depot-specific effects of the PPARγ agonist rosiglitazone on adipose tissue glucose uptake and metabolism. WT Festuccia, P-G Blanchard, V Turcotte, M Laplante, M Sariahmetoglu, DN Brindley and Y Deshaies. J Lipid Res. 50 (2009) 1185-1194. IF = 5.59
180. The PPARγ agonist rosiglitazone enhances rat brown adipose tissue lipogenesis from glucose without altering glucose uptake. WT Festuccia, P-G Blanchard, V Turcotte, M Sariahmetoglu, DN Brindley, D Richard, Y Deshaies. Am J Physiol. 296 (2009) R1327-1335. IF = 3.33.
181. Lipid phosphate phosphohydrolase type 1 (LPP1) degrades extracellular lysophosphatidic acid in vivo. Tomsig JL, Snyder AH, Berdyshev EV, Skobeleva A, Mataya C, Natarajan V, Brindley DN, Lynch KR. Biochem J. 419 (2009) 611-618. IF = 4.90
182. Concurrent Lpin1 and NrCAM mouse mutations result in severe peripheral neuropathy with transitory hind limb paralysis. DS Douglas, J Moran, JR Bermingham, Jr., X-J Chen , DN Brindley, B Soliven, D Beier, and B Popko, J Neurosci. 30 (2009) 12089-12100. IF = 7.92.
183. Skeletal Muscle Lipogenic Protein Expression is Not Different Between Lean and Obese Humans; a Potential Factor in Ceramide Accumulation. AB Thrush, DN Brindley, A Chabowski3, GJ Heigenhauser and DJ Dyck. J Clin Endocrinol Metab, 94 (2009) 5053-5061. IF = 6.37.
Page 3
184. Lipid Phosphate Phosphatases and Signaling. DN Brindley and C. Pilquil. J. Lipid Res. 50 (2009) S225-230. Refereed review. IF = 5.59
185. Phosphatidate degradation: phosphatidate phosphatases (lipins) and lipid phosphate phosphatases. DN Brindley, C Pilquil C, M Sariahmetoglu, K. Reue K. Biochim. Biophys. Acta, Molecular and Cell Biology of Lipids, 1791, (2009), 956-961. Refereed review. IF = 5.2
186. A lipin-2 missense mutation in Majeed Syndrome abolishes lipin-2 phosphatidate phosphatase activity but maintains lipin-2 coactivator function. J Donkor, P Zhang, S Wong, J Dewald, BPC Kok, DN Brindley and Karen Reue, J Biol Chem. 284 (2009) 29968-29978. IF = 5.12
187. Increased expression of enzymes for sphingosine 1-phosphate turnover and signaling in human decidua during late pregnancy. Y Yamamoto, DM Olson, M Bennekom, DN Brindley and DG Hemmings. Biol Rep, 82 (2010) 628-635. IF = 3.88.
188. Shedding light on the enigma of myocardial lipotoxicity: the involvement of known and putative regulators of fatty acid storage and mobilization. Brindley DN, Kok BP, Kienesberger PC, Lehner R, Dyck JR. Am J Physiol Endocrinol Metab. 298 (2010) E897-908. IF = 4.75.
189. Regulation of lysophosphatidate signaling by autotaxin and lipid phosphate phosphatases with respect to tumor progression, angiogenesis, metastasis and chemo-resistance. N Samadi, R Bekele, D Capatos, G Venkatraman, M Sariahmetoglu and DN. Brindley. Biochimie, 93 (2011) 61-70, Aug 13. [Epub ahead of print]. Refereed review. IF = 3.42.
190. Lipins from plants are phosphatidate phosphatases that restore lipid synthesis in a pah1Δ mutant strain of Saccharomyces cerevisiae. E Mietkiewska, RMP Siloto, J Dewald, S Shah, DN Brindley, RJ Weselake, FEBs Journal, 278 (2011) 764-775. IF = 3.34.
191. Lysophosphatidate Induces Chemo-resistance by Releasing Breast Cancer Cells from Taxol-induced Mitotic Arrest. N Samadi, RT Bekele, IS Goping, LM Schang and DN Brindley. PLoS ONE 2011;6(5):e20608. Epub 2011 May 27. IF = 4.54.
192. Relationship of glucose and oleate metabolism to cardiac function in lipin-1 deficient (fld) mice. Kok BP, Kienesberger PC, Dyck JR, Brindley DN. J Lipid Res. 53 (2012) 105-18. Epub 2011 Nov 5. IF = 5.59
193. Unlike two peas in a pod: Lipid phosphate phosphatases and phosphatidate phosphatases. B Kok, G Venkatraman, D Capatos and DN Brindley. Chem Rev. 112 (2012) 5121-5146. IF = 42.05.
194. Mouse lipin-1 and lipin-2 cooperate to maintain glycerolipid homeostasis in liver and aging cerebellum. JR Dwyer, J Donkor, P Zhang, LS. Csaki, L Vergnes, JM Lee, J Dewald, DN Brindley, E Atti, S Tetradis, Y Yoshinaga, PJ de Jong, LG Fong, SG Young and K Reue. Proc Natl Acad Sci. USA. 109 (2012) E2486-2495, IF = 10.47.
195. Role of the autotaxin-lysophosphatidate axis in cancer resistance to chemotherapy and radiotherapy. DN Brindley, FT Lin and GJ Tigyi, Biochim. Biophys. Acta, 1831 (2013) 74-85. IF = 5.27.
196. Phosphorylation of lipin 1 and charge on the phosphatidic acid head group control its phosphatidic acid phosphatase activity and membrane association. JM Eaton, GR Mullins, DN Brindley and TE Harris, J Biol Chem. 288 (2013) 9933-9945. IF = 5.12
197. Differential regulation of the expressions of the lipins, PPARα and PGC-1α in heart compared to liver. BPC Kok, JRB Dyck, TE. Harris and DN Brindley, J Lipid Res, 54 (2013) 1662-1677. IF = 5.59
Book Chapters, Books and Reviews: 2008-2013 (67 total) 62. Lipids in signal transduction and the metabolic syndrome. DN Brindley, Spectrum, V Paetkau and N
Madsen, Editors, 2008, pp 230-241, Printorium, Victoria, BC. 63. Lipid mediators and modulators of neural function: Lysophosphatidate and lysolipids. DN Brindley and
A. U. Bräuer. 2009. Handbook of Neurochemistry and Molecular Biology, vol 8, Neural Lipids. 64 Phosphatidate phosphatases (lipins). DN Brindley, B Kok, Lipid Library, American Oil Chemists Society. 65 Lipid phosphate phosphatases and signaling by lysolipid receptors. G Venkatraman and DN Brindley. In
Lysolipid Receptors: Signaling and Biochemistry, John Wiley and Sons Inc, NY, USA, Ch.11, 2012. 66 Role of autotaxin and lysophosphatidate in cancer progression and resistance to chemotherapy and
radiotherapy. RT Bekele and DN Brindley. Clinical Lipidology, 7, (2012) 313-328. 67 Myocardial Fatty Acid Metabolism and Lipotoxicity in the Setting of Insulin Resistance. BP Kok and DN
Brindley. Heart Failure Clinics, Elsevier, 2012: 8, 643-661.
.
HEMMINGS, Denise G. Page 1 of 3 Biographical Sketch
BIOGRAPHICAL SKETCH
NAME Denise G. Hemmings
POSITION TITLE Associate Professor Division of Reproductive Services Department of Obstetrics & Gynecology University of Alberta
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable.)
INSTITUTION AND LOCATION DEGREE (if applicable) MM/YY FIELD OF STUDY
Department of Genetics University of Alberta, Edmonton, Canada
BSc
09/77-05/81
Genetics
Department of Immunology, University of Alberta, Edmonton, Canada
Research Student
04/80-09/81 Immunology/Supervisor: Thomas Wegmann PhD
Jackson Laboratory Bar Harbor, Maine, USA
Summer Student
Summer 81 Immunology/Supervisor: George Carlson PhD
Department of Immunology University of Alberta, Edmonton, Canada
Masters (incomplete)
09/81-03/84 Immunology/Supervisor: Thomas Wegmann PhD
Dept of Medical Microbiology & Immunology University of Alberta, Edmonton, Canada
PhD 09/94-08/01 Reproductive Immunology/ Supervisor: L. Guilbert PhD
Department of Obstetrics & Gynecology University of Alberta, Edmonton, Canada
Post-Doctoral Fellow
01/09-06/05 Physiology/Supervisor: Sandra Davidge PhD
A. Employment
2011 – present Adjunct Associate Professor, Medical Microbiology & Immunology 2011 – present Associate Professor, Obstetrics & Gynecology 2009 – present Chair, Women in Scholarship, Engineering, Science & Technology (WISEST)
An initiative of the Office of VP (Research) WISEST, now 30 years old, has a mandate to strengthen society by increasing gender and ethnic diversity in science, engineering and technology careers. WISEST does this through exciting programs, meaningful networks and mentorship.
2008 – 2011 Adjunct Assistant Professor, Medical Microbiology & Immunology 2005 – 2011 Assistant Professor, Obstetrics & Gynecology
B. Professional Activities DISTINCTIONS & RECOGNITIONS 2010 – 2015 CIHR New Investigator Salary Support Distinction 2010 Mentoring Award, Sanofi-Aventis BioTalent Challenge 2009 – 2010 Minerva Mentoring Award, Alberta Women’s Science Network 2007 CIHR IHDCYH Lectureship
SCIENTIFIC REVIEW COMMITTEES 2012 – present Member, Scientific Review Committee, CIHR, Clinical Investigation A Committee Feb 2012 Member, Scientific Review Committee, NIAID/NIH, Special Emphasis Panel for RFA on Strategies for Protection of Pregnant Women and Infants Against Infectious Diseases 2009 – present Member, Scientific Review Committee, AHFMR/AI-HS Conference Grants 2007 – present Member, Scientific Review Committee, WCHRI, University of Alberta 2009 – 2011 Member, Scientific Review Committee IVa, Heart & Stroke Foundation of Canada
.
HEMMINGS, Denise G. Page 2 of 3 Biographical Sketch
MEMBERSHIP ON SOCIETY EXECUTIVE COUNCILS 2013 – present Member, International Pregnancy Research Alliance 2009 – present Member, International Federation of Placentas Association (IFPA) Executive 2008 – 2010 Basic Science Council Member, Perinatal Research Society (Elected) SCIENTIFIC PROGRAM/ORGANIZING COMMITTEES 2013 Aspen/Snowmass Perinatal Biology Symposium – Co-organizer and scientific committee 2012 No Name Meeting – Co-organizer and scientific committee 2013 International Fed of Placentas Assoc (IFPA) Scientific Committee, Whistler, Canada 2012 International Fed of Placentas Assoc (IFPA) Scientific Committee, Hiroshima, Japan 2010 International Fed of Placentas Assoc (IFPA) Scientific Committee, Santiago, Chile MEMBERSHIPS OF RESEARCH GROUPS 2012 – present Li Ka Shing Virology Institute, University of Alberta 2008 – present Cardiovascular Research Centre (elected), University of Alberta 2007 – present Women and Children’s Health Research Institute (WCHRI), University of Alberta MEMBERSHIPS OF SOCIETIES 2008 – present Canadian Society of Atherosclerosis, Thrombosis and Vascular Biology 2005 – present Perinatal Research Society (elected) 2005 – present Society for Gynecologic Investigation (elected) 2005 – present American Physiological Society 2005 – present Canadian Hypertension Society 2005 – present Society for the Study of Reproduction KNOWLEDGE EXCHANGE THROUGH INVITED PRESENTATIONS (selected from last 5 years) 1. International Federation of Placenta Associations 2013, “Novel insights into the regulation of
vascular tone by sphingosine 1-phosphate.” Whistler, Canada, September 11-14, 2013 2. FASEB Summer Research Conference, Lysophospholipid and Other Related Mediators – From
Bench to Clinic. “Novel insights into the regulation of vascular tone by sphingosine 1-phosphate.” Niseko, Japan, August 4-9, 2013
3. No Name Society Annual Meeting. “S1P and dual regulation of vascular permeability and vascular tone.” Lake Louise, Alberta, October 21, 2012 (Co-organized this meeting)
4. CIHR-IHDCYH Scientific Forum. “Sphingosine 1-phosphate: A double-edged sword in pregnancy.” Edmonton, Alberta, October 15, 2012
5. Obstetrics and Gynecology Department at Juntendo University. “Impact of cytomegalovirus infection on maternal vascular function.” Tokyo, Japan, September 25, 2012
6. No Name Society Annual Meeting. “Cytomegalovirus glycoprotein B treatment enhances endothelial-dependent vasodilation in pressurized uterine arteries.” Tanque Verde Ranch, Tuscon, Arizona, November 11, 2011 (attendance by invite only)
7. 3rd CIHR-IHDCYH Research Symposium for New Investigators and Trainees. “Post-doc to PI.” Banff, Alberta, February 17, 2011
8. No Name Society Annual Meeting. “Direct and indirect effects of cytomegalovirus on vascular function of uterine arteries.” Quartz Mountain Resort, Lone Wolf, OK, November 13, 2010 (attendance by invite only)
9. University of Vermont College of Medicine. “Cytomegalovirus and vascular function in pregnancy.” Burlington, VT, USA, February 23, 2010
.
HEMMINGS, Denise G. Page 3 of 3 Biographical Sketch
10. No Name Society Annual Meeting. “Sphingosine 1-phosphate signaling in pregnancy.” Bandera, TX, USA, Oct 23, 2009 (attendance by invite only)
11. Baker IDI Heart & Diabetes Institute, - “Cytomegalovirus and vascular function in pregnancy.” Melbourne, AU, October 2, 2009
12. Academic Division of Child Health, “Cytomegalovirus infection and maternal vascular dysfunction.” University of Nottingham UK, March 27, 2009
13. Reproductive Sciences, “Cytomegalovirus infection and maternal vascular dysfunction.” University of Newcastle, UK, March 23, 2009
14. Institute of Pharmacy and Biomedical Sciences, “Cytomegalovirus, sphingosine 1-phosphate and vascular function,” University of Strathclyde, Glasgow, UK, March 16, 2009
15. Grand Rounds. “Is the placenta a protected reservoir for pathogens.” Queen’s University, Kingston, ON, Canada, October 23, 2008
16. Department of Anatomy and Cell Biology. “Vascular effects of cytomegalovirus infection in pregnancy.” Queen’s University, Kingston, ON, Canada, October 23, 2008
17. No Name Society Annual Meeting. “Cytomegalovirus and vascular dysfunction in pregnancy.” Madison, WI, USA, May 1, 2008 (attendance by invite only)
C. Peer Reviewed Articles 2008-2013 (trainees are underlined)
1. Arbuckle TE, Fraser WD, Fisher M, Davis K, Liang CL, Lupien N, Bastien S, Velez MP, von Dadelszen P, Hemmings DG et al, “Cohort Profile: The Maternal-Infant Research on Environmental Chemicals (MIREC) Research Platform,” Paediatric and Perinatal Epidemiology, in press
2. Gombos RB, Brown JC, Teefy J, Gibeault RL, Conn KL, Schang LM, Hemmings DG. “Vascular dysfunction in young, mid-aged and aged mice with latent cytomegalovirus infections,” Am J Physiol Heart Circ Physiol 304(2):H183-94, 2013 (IF = 3.88, ranked 25 out of 114 Cardiovascular journals)
3. Gombos RB, Teefy J, Lee A, Hemmings DG. Impact of local endothelial challenge with cytomegalovirus or glycoprotein B on vasodilation in intact pressurized arteries from non-pregnant and pregnant mice. Biol Reprod 87(4):83, 2012 (IF = 3.87, ranked 4 out of 26 Reproductive Biology journals)
4. Davey A, Eastman L, Hansraj P, Hemmings DG. Human cytomegalovirus is protected from inactivation by reversible binding to villous trophoblasts,” Biol Reprod 85(1):198-207, 2011(IF = 3.87, ranked 4 out of 26 Reproductive Biology journals)
5. Gombos R, Hemmings DG. “Differential effects on nitric-oxide-mediated vasodilation in mesenteric and uterine arteries from cytomegalovirus-infected mice,” Am J Physiol Heart Circ Physiol 299(4): H1124-34, 2010 (IF = 3.88, ranked 25 out of 114 Cardiovascular journals)
6. Yamamoto Y, Olson DM, van Bennekom M, Brindley DN, Hemmings DG, “Increased expression of enzymes for sphingosine 1-phosphate turnover and signaling in human decidua during late pregnancy,” Biol Reprod 82(3):628-35, 2010 (IF = 3.87, ranked 4 out of 26 Reproductive Biology journals)
7. Gombos R, Wolan V, McDonald K, Hemmings DG. “Impaired vascular function in mice with an active cytomegalovirus infection.” Am J Physiol Heart Circ Physiol 296(4):H937-45, 2009 (IF = 3.88, ranked 25 out of 114 Cardiovascular journals)
Chapters/Reviews/Conference Proceedings 1. Lash GE, Burton GJ, Chamley LW, Clifton VL, Constancia M, Crocker IP, Dantzer V, Desoye G, Drewlo
S, Hemmings DG, Hiendleder S, Kalionis B, Keelan JA, Kudo Y, Lewis RM, Manuelpillai U, Murthi P, Natale D, Pfarrer C, Robertson S, Saffery R, Saito S, Sferruzzi-Perri A, Sobrevia L, Waddell BJ, Roberts CT. IFPA meeting 2009 workshops report. Placenta, Mar; 31 Suppl: S4-20, 2010 (IF = 2.99, ranked 9 out of 26 Reproductive Biology journals)
Page 1
BIOGRAPHICAL SKETCH NAME Susan Pyne
POSITION TITLE Professor of Molecular Signalling, University of Strathclyde
INSTITUTION AND LOCATION DEGREE
(if applicable) MM/YY FIELD OF STUDY
University of Nottingham, Nottingham, UK BSc 1982 Biochemistry & Chemistry University of Birmingham, Birmingham, UK Ph.D. 1986 Biochemistry
A. Employment 2005/11-present Professor, Institute for Pharmacy and Biomedical Sciences, University of Strathclyde 2003/09-2005/10 Reader, Dept. Physiology & Pharmacology, University of Strathclyde 2001/10-2003/08 Snr Lecturer, Dept. Physiology & Pharmacology, University of Strathclyde 1993/10-2001/09 Wellcome Trust Senior Research Fellow in Basic Biomedical Science (renewed in 1998), University
of Strathclyde 1990/10-1993/09 Post-doctoral scientist and joint grant holder (The Wellcome Trust), Dept. Physiology &
Pharmacology, University of Strathclyde 1987/10-1990/09 PDF and joint grant holder (MRC), Department of Biochemistry, University of Glasgow 1986/03-1987/10 PDF (funded by Amersham International plc.) Department of Biochemistry, University of Glasgow B. Professional Activities
Committee Membership within Professional Organisations 1994-1999 Member of the Lipid Group Committee, Biochemical Society (maximum term) 1999-2003 IUPHAR sub-committee Endothelial Differentiation Gene receptor nomenclature 2003-2005 Cell and Immunology Study Section, National Institute of Health, USA 2010-2012 BBSRC Pool of Experts (Committees A and D)
2012-present Scientific advisory panel, Tenovus (Scottish medical charity) 2013-present BBSRC Committee D member Membership of Professional Organisations
1982-present Biochemical Society (editorial advisor 1994-2008); Ambassador to Strathclyde University 1994-2000 British Pharmacological Society 1998-present American Society for Biochemistry and Molecular Biology
Conferences Organised and Chaired 1992 The 3rd Scottish Signal Transduction Meeting, University of Strathclyde. 1996 Biochemical Society/British Society for Immunology, Harrogate, U.K. Lipid Group Symposium on: Lipids as Regulators of Cell Function 1999 Biochemical Society, Glasgow Lipid Group Symposium on: Sphingolipids 2001 Biochemical Society at Trinity College, Dublin Mol./Cellr. Pharmacol./Lipid Group Symposium on: Lipid metabolising enzymes 2005 Bioscience2005 at SECC, Glasgow
Mol./Cellr. Pharmacol Group Symposium on: Sphingosine 1-phosphate and Lysophosphatidic acid 2010 8th International Sphingolipid meeting, Glasgow 2011 Biochem Soc. Centenary Meeting, Edinburgh: Symposium on Lipid Signalling Research Journals Editorial Boards 2010-present Editor: British Journal of Pharmacology 2006-present Co-Editor: Cellular Signalling 2003-2012 Editorial Board: Prostaglandins and Other Lipid Mediators 1994-2008 Editorial Advisory Panel: Biochemical Journal
C. Honors: 1993-2001 Wellcome Trust Senior Research Fellow in Basic Biomedical Sciences D. Peer Reviewed Articles 2008-2013 (from 116 total)
Coats, P., Kennedy, S., Pyne, S., Wainwright, C.L. & Wadsworth, R.M. (2008) Inhibition of non-Ras protein farnesylation reduces in-stent restenosis. Atherosclerosis. 197, 515-523.
Page 2
Long, J.S., Pyne, N.J. & Pyne, S. (2008) Lipid phosphate phosphatases form homo- and hetero oligomers: Catalytic competency, sub-cellular distribution and function. Biochem. J. 411, 371-377.
Pyne, N.J. & Pyne, S (2008) Sphingosine 1-phosphate, lysophosphatidic acid and growth factor signalling and termination. Biochim. Biophys.Acta 1781, 467-476.
Kennedy, S., Kane, K.A., Pyne, N. J. & Pyne, S. (2009) Targeting sphingosine 1-phosphate signalling for cardioprotection. Cur. Opin. Pharmacol. 9, 194-201.
Pyne, S., Lee, S.C., Long, J. & Pyne, N. J. (2009) Role of sphingosine kinases and lipid phosphate phosphatases in regulating spatial sphingosine 1-phosphate signalling in health and disease. Cell Signal. 21, 14-21.
Pyne, N. J., Long, J.S., Lee, S.C., Loveridge, C., Gillies, L. & Pyne, S. (2009) New aspects of sphingosine 1-phosphate signaling in mammalian cells. Advances in Enzyme Regulation 49, 214-221.
Gillies, L., Lee, S.C., Long, J.S., Ktistakis, N., Pyne, N.J. & Pyne, S. (2009) The sphingosine 1-phosphate receptor-5 and Sphingosine kinase 1 and 2 are localized in the centrosome: Role in regulating cell division. Cell Signal 21, 675-684.
Ramachandran, S., Chu, U.B., Muvlyatov, T.A., Pal, A., Pyne, S. & Ruoho, A.E. (2009) The sigma1 receptor interacts with N-alkyl amines and endogenous sphingolipids. Eur. J. Pharmacol. 609, 19-26.
Rodgers, A., Mormeneo, D., Long, J.S., Delgado, A., Pyne, N.J. & Pyne, S. (2009) Sphingosine 1-phosphate regulation of extracellular signal regulated kinase-1/2 in embyronic stem cells. Stem Cell Dev. 18, 1319-1330.
McDonald, R.A., Pyne, S., Pyne, N.J., Wainwright, C.L. & Wadsworth, R.M. (2010) The sphingosine kinase inhibitor N, N-dimethylsphingosine inhibits neointimal hyperplasia. Br. J. Pharmacol. 159, 543-553.
Pyne, N.J. & Pyne, S. (2010) Sphingosine 1-phosphate and cancer. Nature Rev. Cancer 10, 489-503. Long, J.S., Edwards, J., Watson, C., Tovey, S., Mair, K., Schiff, R., Natarajan, V., Pyne, N.J., & Pyne, S. (2010)
Sphingosine kinase 1 induces tolerance to human Epidermal growth factor receptor 2 and prevents formation of a migratory phenotype in response to sphingosine 1-phosphate in estrogen receptor positive breast cancer cells. Mol. Cell. Biol. 30, 3827-3841.
Mair, K., Robinson, E., Kane, K., Pyne, S., Brett, R., Pyne, N.J. & Kennedy, S. (2010) Interaction between anandamide and sphingosine-1-phosphate in mediating vasorelaxation in rat coronary artery. Br. J. Pharmacol. 161, 176-192.
Tonelli, F., Lim, K.G., Loveridge, C., Long, J., Pitson, S.M., Tigyi, G., Bittman, R., Pyne, S. & Pyne, N.J. (2010) FTY720 and (S)-FTY720 vinylphosphonate inhibit sphingosine kinase 1 and promotes its proteasomal degradation in human pulmonary artery smooth muscle, breast cancer and androgen-independent prostate cancer cells. Cell. Signal. 22, 1536-1542.
Long, J.S., Fujiwara, Y., Edwards, J., Tannahill, C., Tigyi, G., Pyne, S. & Pyne, N.J. (2010) Sphingosine 1-phosphate 4 uses HER2 (ErbB2) to regulate extracellular signal regulated kinase-1/2 in MDA-MB-453 breast cancer cells. J. Biol. Chem. 285, 35957-35966.
Watson, C., Long, J.S., Orange, C., Tannahill, C.L., Mallon, E., McGlynn, L.M., Pyne, S., Pyne, N.J. & Edwards, J. (2010) High Expression of Sphingosine 1-Phosphate Receptors, S1P1 and S1P3, Sphingosine Kinase 1, and Extracellular Signal-Regulated Kinase-1/2 Is Associated with Development of Tamoxifen Resistance in Estrogen Receptor-Positive Breast Cancer Patients. Am. J. Pathology 177, 2205-2215.
Loveridge, C., Tonelli, F., Leclercq, T., Lim, K.G., Long, S., Berdyshev, E., Tate, R.J., Natarajan, V., Pitson, S.M., Pyne, N.J. & Pyne, S. (2010) The sphingosine kinase 1 inhibitor 2-(p-hydroxyanilino)-4-(p-chlorophenyl)thiazole induces proteosomal degradation of sphingosine kinase 1 in mammalian cells. J. Biol. Chem. 285, 38841-38852.
Berdyshev, E.V., Gorshkova, I., Usatyuk, P., Kalari, S., Zhao. Y., Pyne, N.J., Pyne, S., Sabbadini, R.A., Garcia, J. & Natarajan, V. (2011) Intracellular S1P generation is essential for S1P-induced motility of Human Lung Endothelial Cells: Role of Sphingosine Kinase 1 and Sphingosine-1-Phosphate Lyase. PLOS1 6,16571.
Lim, K.G., Tonelli, F., Li, Z., Lu, X., Bittman, R., Pyne, S. & Pyne, N.J. (2011) FTY720 analogues as sphingosine kinase 1 inhibitors: Enzyme inhibition kinetics, allosterism, proteasomal degradation and actin rearrangement in MCF-7 breast cancer cells. J. Biol. Chem. 286, 18633-18640.
Pyne, N.J. & Pyne, S. (2011) Selectivity and specificity of sphingosine 1-phosphate receptor ligands: ‘off-targets’ or complex pharmacology. Frontiers in Pharmacology 2, 26 (1-4).
Pyne, S. & Pyne, N.J. (2011) Translational aspects of sphingosine 1-phosphate biology. Trends in Molecular Medicine 17, 463-472.
Pyne, N.J. & Pyne, S. (2011) Receptor tyrosine kinase-G-protein coupled receptor signalling platforms: Out of the shadow? Trends in Pharmacological Sciences 32, 443-450.
Lim, K.G., Sun, C., Bittman, R., Pyne, N.J. & Pyne, S. (2011) (R)-FTY720 methyl ether is a specific sphingosine kinase 2 inhibitor: effect on sphingosine kinase 2 expression in HEK 293 cells and actin rearrangement and survival of MCF-7 breast cancer cells. Cell. Signal. 23, 1590-1595.
Page 3
Pyne, S., Bittman, R. & Pyne, N.J. (2011) Sphingosine kinase inhibitors and cancer: Seeking the Golden Sword of Hercules. Cancer Res. 71, 6576-6582.
Pyne, N.J., Tonelli, F., Lim, K.G., Long, S., Edwards, J. & Pyne, S. (2012) Sphingosine 1-phosphate signalling in cancer. Biochem. Soc. Trans. 40, 94-100.
Lim, K.G., Gray, A., Pyne, S. & Pyne N.J. (2012) Resveratrol dimers are novel sphingosine kinase 1 inhibitors and affect sphingosine kinase 1 expression and cancer cell growth and survival. Br. J. Pharmacol. 166, 1605-1616.
Ohotski, J., Long, J.S., Orange, C., Elsberger, B., Mallon, E., Dought, J., Pyne, S., Pyne, N.J. & Edwards, J. (2012) High expression of the Sphingosine 1-phosphate receptor 4 and Sphingosine kinase 1 is associated with outcome in estrogen negative breast cancer. Br. J. Cancer 106, 1453-1459.
Lim, K.G., Tonelli, F., Berdyshev, E.V., Gorshkova, I., Leclercq, T., Pitson, S.M., Bittman, R., Pyne, S. & Pyne, N.J. (2012) Inhibition kinetics and regulation of sphingosine kinase 1 expression in prostate cancer cells: Functional differences between sphingosine kinase 1A and 1B. Int.J.Biochem. Cell Biol. 44, 1457-1464.
Pyne, S., Edwards, J.E., Ohotski, J. & Pyne, N.J. (2012) Sphingosine 1-phosphate receptors and spphingosine kinase 1: novel biomarkers for clinical prognosis in cancer. Front Mo and Cell Oncology 2, 168.
Pyne, N.J., Tonelli, F., Lim, K.G., Long, S., Edwards, J. & Pyne, S. (2012) Targeting sphingosine kinase 1 in cancer. Advances in Biological Regulation 52, 31-38.
Ohotski, J., Edwards, J., Elsberger, B., Watson, C., Orange, C., Mallon, E., Pyne, S. & Pyne, N.J. (2013) Identification of novel functional and spatial interactions between sphingosine kinase 1, sphingosine 1-phosphate receptors and other signaling proteins that affect prognostic outcome in estrogen receptor positive breast cancer. Int. J. Cancer 132, 605-616.
Pyne, S., Dubois, G. & Pyne, N.J. (2013) Role of sphingosine 1-phosphate and lysophosphatidic acid in fibrosis. Biochim. Biophys. Acta. 1831, 228-238.
Tonelli, F., Alossaimi, M.., Williamson, L., Tate, R.J., Watson, D.G., Chan, E., Bittman, R., Pyne, N.J. & Pyne, S. (2013) The sphingosine kinase inhibitor 2-(p-hydroxyanilino)-4-(p-chlorophenyl)thiazole reduces androgen receptor expression via an oxidative stress-dependent mechanism. British Journal of Pharmacology 168, 1497-1505.
Pyne, N.J. & Pyne, S. (2013) Sphingosine 1-phosphate is the missing link between inflammation and colon cancer. Cancer Cell 23, 5-7. Watson, D., Tonelli, F., Alossaimi, M, Williamson, L., Chan, E., Gorshkova, I., Berdyshev, E., Bittman, R., Pyne, N.J. & Pyne, S. (2013) The role of sphingosine kinase 1 and 2 in regulating the Warburg effect in prostate cancer cells. Cell. Signal. 25, 1011-1017.
Baek, D.J., MacRitchie, N., Pyne, N.J., Pyne, S. & Bittman, R. (2013) The synthesis of selective inhibitors sphingosine kinase 1. Chem. Comm. 49, 2136-2138.
Pyne, N.J. & Pyne, S. (2013) Lysophospholipid receptor signalling platforms: The receptor tyrosine kinase-G-protein coupled receptor signaling complex (Lysophospholipid Receptors, Signaling and Biochemistry, Ed: J. Chun, W. Moolenaar, S. Spiegel) (in press).
Pyne, S. & Pyne, N.J. (2013) New perspectives on the role of sphingosine 1-phosphate in cancer. Handb. Exp. Pharmacol. (SpringerWein, NY; Ed: I. Petrache and E. Gulbins) 216, 55-71.
Liu, Z., MacRitchie, N., Pyne, S., Pyne, N.J. & Bittman, R. (2013) Synthesis of (S)-FTY720 vinylphosphonate analogues and evaluation of their potential as sphingosine kinase 1 inhibitors. Bio-organic Med. Chem. 21, 2503-2510.
Tonelli, F., Alossaimi, Natarajan, V., Gorshkova, I., Berdyshev, E., Bittman, R., Watson, D.G., Pyne, S. & Pyne, N.J. (2013) Role of sphingosine kinase 1 and 2 in regulating the metabolome and survival of prostate cancer cells. Biomolecules 3, 316-333.
Gutiérrez-Martínez, G., Fernández-Ulibarri, I., Lázaro-Diéguez, F., Johannes, L., Pyne, S., Sarri, E. & Egea, G. (2013) Lipid phosphate phosphatase 3 participates in transport carrier formation and protein trafficking in the early secretory pathway. J. Cell Sci. 126, 2641-55. doi: 10.1242/jcs.117705.
Pyne, N.J. & Pyne, S. (2013) Sphingosine kinase 1 enables communication between melanoma cells and fibroblasts that provides a new link to metastasis. Oncogene (in press).
Byun, H-S., MacRitchie, N., Pyne, S., Pyne, N.J. & Bittman, R. (2013) Novel sphingosine-containing analogues selectively inhibit sphingosine kinase (SK) isozymes, induce SK1 proteasomal degradation and reduce DNA synthesis in human pulmonary arterial smooth muscle cells. Med.Chem.Comm. (in press).
Pyne, N.J., Ohotski, J., Bittman, R. & Pyne, S. (2013) Role of Sphingosine 1-phosphate in inflammation and cancer. Advances in Biological Regulation (in press). Pyne NJ, Pyne S. (2013) Sphingosine kinase 1 enables communication between melanoma cells and fibroblasts that provides a new link to metastasis. Oncogene. Jul 22. doi: 10.1038/onc.2013.292.
Page 1
BIOGRAPHICAL SKETCH NAME Nigel J Pyne
POSITION TITLE Professor of Molecular Pharmacology, University of Strathclyde
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable.)
INSTITUTION AND LOCATION DEGREE (if applicable) MM/YY FIELD OF STUDY
University of Birmingham, Birmingham, England B.Sc. Upper Second 1982 Biochemistry
University Manchester Institute of Science and Technology, Manchester, England Ph.D. 1986 Biochemistry
A. Employment 1985-89 MRC Post-doctoral Fellow in the Department of Biochemistry, University of Glasgow, Scotland 1989-91 Probationary Lecturer, University of Strathclyde, Scotland 1991-94 Lecturer in Pharmacology, University of Strathclyde, Scotland 1994-1998 Senior Lecturer in Pharmacology, University of Strathclyde, Scotland 1998-2000 Reader in Pharmacology, University of Strathclyde, Scotland 2006-2008 SIPBS Head of Research, University of Strathclyde, Scotland 2000-present Professor of Molecular Pharmacology, University of Strathclyde, Scotland B. Professional Activities 1989-present Biochemical Society Member 1994-present British Pharmacological Society Member 2003-2006 American Society for Biochemistry and Molecular Biology Member 2013 Spin out company Founder-FourBio Conferences Organised 1992 The 3rd Scottish Signal Transduction Meeting, University of Strathclyde, UK. 1994 The 19th Meeting of the British Inflammation Research Society, University of Strathclyde, UK. 1996 The 3rd International Meeting on Phosphodiesterases: 'From Genes to Therapies, University of Strathclyde,
UK. 2008 British Pharmacological Society Focused Meeting on Lysophospholipids, Novartis, UK. 2008 Gordon Research Conferences Phosphodiesterases, Il Ciocco, Italy: Conference Chair. Research Journals Editorial Boards Member of the Biochemical Journal Editorial Advisory Panel (1985-1999) Member of the Biochemical Journal Editorial Board (1999-2006) Member of the British Journal of Pharmacology Editorial Board (1998-2002) Deputy Editor in Chief Cellular Signalling (2003-present) Member of Advances in Biological Regulation Editorial Board (2011-present) C. Honors 1989 Juselius Foundation and Welcome Trust Fellowship for research at University of Helsinki, Finland 1995 Sandoz Prize in Pharmacology (awarded by the British Pharmacological Society) 2009- Elected member of The Academy of Sciences, University of Bologna C. Peer Reviewed Articles 2008-2013 (from 155 total)
Long, J.S., Pyne, N.J. & Pyne, S. (2008) Lipid phosphate phosphatases form homo- and hetero oligomers: Catalytic competency, sub-cellular distribution and function. Biochem. J. 411, 371-377.
Gorshkova, I., He, D., Berdyshev, E., Usatuyk, P., Burns, M., Kalari, S., Pendyal, S, Garcia, J., Pyne, N.J., Brindley, D.N. & Natarajan, V. (2008) Protein Kinase C ε Regulates Sphingosine-1-Phosphate-Mediated Migration of Human Lung Endothelial Cells through Activation of Phospholipase D2, Protein Kinase ζ, and Rac1. J.Biol.Chem.283, 11794-11806.
Pyne, N.J. & Pyne, S (2008) Sphingosine 1 phosphate, lysophosphatidic acid and growth factor signalling and termination. Biochim. Biophys.Acta 1781, 467-476.
Page 2
Kennedy, S., Kane, K.A., Pyne, N. J. & Pyne, S. (2009) Targeting sphingosine 1 phosphate signalling for cardioprotection. Cur. Opin. Pharmacol. 9, 194-201.
Pyne, S., Lee, S.C., Long, J. & Pyne, N. J. (2009) Role of sphingosine kinases and lipid phosphate phosphatases in regulating spatial sphingosine 1-phosphate signalling in health and disease. Cell Signal. 21, 14-21.
Pyne, N. J., Long, J.S., Lee, S.C., Loveridge, C., Gillies, L. & Pyne, S. (2009) New aspects of sphingosine 1 phosphate signaling in mammalian cells. Advances in Enzyme Regulation 49, 214-221.
Gillies, L., Lee, S.C., Long, J.S., Ktistakis, N., Pyne, N.J. & Pyne, S. (2009) The sphingosine 1 phosphate receptor-5 and Sphingosine kinase 1 and 2 are localized in the centrosome: Role in regulating cell division. Cell Signal.21, 675-684.
Ong, W-K., Gribble, F.M., Reimann, F., Lynch M.J., Houslay, M.D., Baillie, G.S., Furman, B.L. & Pyne, N.J. (2009) Role of PDE4 and PDE3 in regulating glucose-induced GLP-1 release from GLUTag cells. Br.J.Pharmacol. 157, 633-44.
Rodgers, A., Mormeneo, D., Long, J.S., Delgado, A., Pyne, N.J. & Pyne, S. (2009) Sphingosine 1 phosphate regulation of extracellular signal regulated kinase-1/2 in embyronic stem cells. Stem Cell Dev. 18, 1319-1330.
Furman, B.L., Ong, W-K. & Pyne, N. J. (2010) Cyclic AMP signalling in islets. Advances in Experimental Medical Biology. 654, 281-304.
McDonald, R.A., Pyne, S., Pyne, N.J., Wainwright, C.L. & Wadsworth, R.M. (2010) The sphingosine kinase inhibitor N, N-dimethylsphingosine inhibits neointimal hyperplasia. Br. J. Pharmacol. 159, 543-553.
Pyne, N.J. & Pyne, S (2010) Sphingosine 1 phosphate and cancer. Nature Rev. Cancer 10, 489-503. Long, J.S., Edwards, J., Watson, C., Tovey, S., Mair, K., Schiff, R., Natarajan, V., Pyne, N.J., & Pyne, S. (2010)
Sphingosine kinase 1 induces tolerance to human Epidermal growth factor receptor 2 and prevents formation of a migratory phenotype in response to sphingosine 1-phosphate in estrogen receptor positive breast cancer cells. Mol. Cell. Biol. 30, 3827-3841.
Mair, K., Robinson, E., Kane, K., Pyne, S., Brett, R., Pyne, N.J. & Kennedy, S. (2010) Interaction between anandamide and sphingosine-1-phosphate in mediating vasorelaxation in rat coronary artery. Br. J. Pharmacol. 161, 176-192.
Tonelli, F., Lim, K.G., Loveridge, C., Long, J., Pitson, S.M., Tigyi, G., Bittman, R., Pyne, S & Pyne, N.J. (2010) FTY720 and (S)-FTY720 vinylphosphonate inhibit sphingosine kinase 1 and promotes its proteasomal degradation in human pulmonary artery smooth muscle, breast cancer and androgen-independent prostate cancer cells. Cell. Signal. 22, 1536-1542.
Valentine, W.J., Kiss, G.N., Liu, J., Shuyu, E., Gotoh, M., Murokami-Murofushi, K., Pham, T.C., Baker, D., Parrill, A.B., Lu, X., Sun, C., Bittman, R., Pyne, N.J. & Tigyi, G. (2010) (S)-FTY720-Vinylphosphonate, an analogue of the immunosuppressive agent FTY720, signals as a pan-antagonist of sphingosine 1-phosphate GPCR and inhibits autotaxin activity. Cell. Signal. 22, 1543-1553.
Long, J.S., Fujiwara, Y., Edwards, J., Tannahill, C., Tigyi, G., Pyne, S. & Pyne, N.J. (2010) Sphingosine 1-phosphate 4 uses HER2 (ErbB2) to regulate extracellular signal regulated kinase-1/2 in MDA-MB-453 breast cancer cells. J. Biol. Chem. 285, 35957-35966.
Watson, C., Long, J.S., Orange, C., Tannahill, C.L., Mallon, E., McGlynn, L.M., Pyne, S., Pyne, N.J. & Edwards, J. (2010) High Expression of Sphingosine 1-Phosphate Receptors, S1P1 and S1P3, Sphingosine Kinase 1, and Extracellular Signal-Regulated Kinase-1/2 Is Associated with Development of Tamoxifen Resistance in Estrogen Receptor-Positive Breast Cancer Patients. Am. J. Pathology 177, 2205-2215.
Loveridge, C., Tonelli, F., Leclercq, T., Lim, K.G., Long, S., Berdyshev, E., Tate, R.J., Natarajan, V., Pitson, S.M., Pyne, N.J. & Pyne, S. (2010) The sphingosine kinase 1 inhibitor 2-(p-hydroxyanilino)-4-(p-chlorophenyl)thiazole induces proteosomal degradation of sphingosine kinase 1 in mammalian cells. J. Biol. Chem. 285, 38841-38852.
Berdyshev, E.V., Gorshkova, I., Usatyuk, P., Kalari, S., Zhao. Y., Pyne, N.J., Pyne, S., Sabbadini, R.A., Garcia, J. & Natarajan, V. (2011) Intracellular S1P generation is essential for S1P-induced motility of Human Lung Endothelial Cells: Role of Sphingosine Kinase 1 and Sphingosine-1-Phosphate Lyase. PLOS1 6, e16571.
Lim, K.G., Tonelli, F., Li, Z., Lu, X., Bittman, R., Pyne, S. & Pyne, N.J. (2011) FTY720 analogues as sphingosine kinase 1 inhibitors: Enzyme inhibition kinetics, allosterism, proteasomal degradation and actin rearrangement in MCF-7 breast cancer cells. J. Biol. Chem. 286, 18633-18640.
Pyne, N.J. & Pyne, S. (2011) Selectivity and specificity of sphingosine 1-phosphate receptor ligands: ‘off-targets’ or complex pharmacology. Frontiers in Pharmacology 2, 26 (1-4).
Pyne, S. & Pyne, N.J. (2011) Translational aspects of sphingosine 1-phosphate biology. Trends in Molecular Medicine 17, 463-472.
Pyne, N.J. & Pyne, S. (2011) Receptor tyrosine kinase-G-protein coupled receptor signalling platforms: Out of the shadow? Trends in Pharmacological Sciences 32, 443-450.
Page 3
Lim, K.G., Sun, C., Bittman, R., Pyne, N.J. & Pyne, S. (2011) (R)-FTY720 methyl ether is a specific sphingosine kinase 2 inhibitor: effect on sphingosine kinase 2 expression in HEK 293 cells and actin rearrangement and survival of MCF-7 breast cancer cells. Cell. Signal. 23, 1590-1595.
Pyne, S., Bittman, R. & Pyne, N.J. (2011) Sphingosine kinase inhibitors and cancer: Seeking the Golden Sword of Hercules. Cancer Res. 71, 6576-6582.
Pyne, N.J., Tonelli, F., Lim, K.G., Long, S., Edwards, J. & Pyne, S. (2012) Sphingosine 1 phosphate signalling in cancer. Biochem. Soc. Trans. 40, 94-100.
Lim, K.G., Gray, A., Pyne, S. & Pyne N.J. (2012) Resveratrol dimers are novel sphingosine kinase 1 inhibitors and affect sphingosine kinase 1 expression and cancer cell growth and survival. Br. J. Pharmacol. 166, 1605-1616.
Ohotski, J., Long, J.S., Orange, C., Elsberger, B., Mallon, E., Dought, J., Pyne, S., Pyne, N.J. & Edwards, J. (2012) High expression of the Sphingosine 1-phosphate receptor 4 and Sphingosine kinase 1 is associated with outcome in estrogen negative breast cancer. Br. J. Cancer 106, 1453-1459.
Lim, K.G., Tonelli, F., Berdyshev, E.V., Gorshkova, I., Leclercq, T., Pitson, S.M., Bittman, R., Pyne, S. & Pyne, N.J. (2012) Inhibition kinetics and regulation of sphingosine kinase 1 expression in prostate cancer cells: Functional differences between sphingosine kinase 1A and 1B. Int. J. Biochem. Cell Biol. 44, 1457-1464.
Pyne, S., Edwards, J.E., Ohotski, J. & Pyne, N.J. (2012) Sphingosine 1-phosphate receptors and spphingosine kinase 1: novel biomarkers for clinical prognosis in cancer. Frontiers of Molecular and Cellular Oncology 2, 168.
Pyne, N.J., Tonelli, F., Lim, K.G., Long, S., Edwards, J. & Pyne, S. (2012) Targeting sphingosine kinase 1 in cancer. Advances in Biological Regulation 52, 31-38.
Gibreil, A.A.Y., Tate. R.J., Yu. Y., Rawson-Lax, E., Hammer, H.M., Tettey J.N.A., Pyne, N.J. & Converse, C.A. (2013) The p.Arg86Gln change in GARP2 (Glutamic Acid-Rich Protein-2) is a common West African-related polymorphism. Gene 515, 155-158.
Ohotski, J., Edwards, J., Elsberger, B., Watson, C., Orange, C., Mallon, E., Pyne, S. & Pyne, N.J. (2013) Identification of novel functional and spatial interactions between sphingosine kinase 1, sphingosine 1-phosphate receptors and other signaling proteins that affect prognostic outcome in estrogen receptor positive breast cancer. Int. J. Cancer 132, 605-616.
Pyne, S., Dubois, G. & Pyne, N.J. (2013) Role of sphingosine 1-phosphate and lysophosphatidic acid in fibrosis. Biochim. Biophys. Acta. 1831, 228-238.
Tonelli, F., Osaimi, M.A., Williamson, L., Tate, R.J., Watson, D.G., Chan, E., Bittman, R., Pyne, N.J. & Pyne, S. (2013) The sphingosine kinase inhibitor 2-(p-hydroxyanilino)-4-(p-chlorophenyl)thiazole reduces androgen receptor expression via an oxidative stress-dependent mechanism. British Journal of Pharmacology 168, 1497-1505.
Pyne, N.J. & Pyne, S. (2013) Sphingosine 1-phosphate is the missing link between inflammation and colon cancer. Cancer Cell 23, 5-7.
Watson, D., Tonelli, F., Al-Osaimi, M, Williamson, L., Chan, E., Gorshkova, I., Berdyshev, E., Bittman, R., Pyne, N.J. & Pyne, S. (2013) The role of sphingosine kinase 1 and 2 in regulating the Warburg effect in prostate cancer cells. Cell. Signal. 25, 1011-1017.
Baek, D.J., MacRitchie, N., Pyne, N.J., Pyne, S. & Bittman, R. (2013) The synthesis of selective inhibitors sphingosine kinase 1. Chem. Comm. 49, 2136-2138.
Pyne, N.J. & Pyne, S. (2013) Lysophospholipid receptor signalling platforms: The receptor tyrosine kinase-G-protein coupled receptor signaling complex (Lysophospholipid Receptors, Signaling and Biochemistry, Ed: J. Chun, W. Moolenaar, S. Spiegel) (in press).
Pyne, S. & Pyne, N.J. (2013) New perspectives on the role of sphingosine 1-phosphate in cancer. Handb. Exp. Pharmacol. (SpringerWein, NY; Ed: I. Petrache and E. Gulbins) 216, 55-71.
Liu, Z., MacRitchie, N., Pyne, S., Pyne, N.J. & Bittman, R. (2013) Synthesis of (S)-FTY720 vinylphosphonate analogues and evaluation of their potential as sphingosine kinase 1 inhibitors. Bio-organic Med. Chem. 21, 2503-2510. Tonelli, F., Al-Osaimi, Natarajan, V., Gorshkova, I., Berdyshev, E., Bittman, R., Watson, D.G., Pyne, S. & Pyne, N.J. (2013) Role of sphingosine kinase 1 and 2 in regulating the metabolome and survival of prostate cancer cells. Biomolecules (2013) 3, 316-333.
Pyne, N.J. & Pyne, S. (2013) Sphingosine kinase 1 enables communication between melanoma cells and fibroblasts that provides a new link to metastasis. Oncogene (in press).
Byun, H-S., MacRitchie, N., Pyne, S., Pyne, N.J. & Bittman, R. (2013) Novel sphingosine-containing analogues selectively inhibit sphingosine kinase (SK) isozymes, induce SK1 proteasomal degradation and reduce DNA synthesis in human pulmonary arterial smooth muscle cells. Med.Chem.Comm. (in press).
Pyne, N.J., Ohotski, J., Bittman, R. & Pyne, S. (2013) Role of Sphingosine 1-phosphate in inflammation and cancer. Advances in Biological Regulation (in press).
Course Evaluation 2013 Science Research Conferences
Lysophospholipid and Other Related Mediators-FromBench to Clinicpresented 8/4/201359 forms submitted
Forms
Section 1 - Scientific Content
General Sessions
The most important areas of current active research were adequately discussed. 4.7
There was a sufficient amount of unpublished research presented. 4.4
The conference helped you generate new ideas for research. 4.6
There was adequate time provided for invited presentations and short talks selected from submitted abstracts. 4.6
The discussion periods were utilized effectively. 4.6
Poster Sessions
The time allocated for poster sessions was effective. 4.6
I am satisfied with the contribution of the poster sessions to the conference. 4.6
Scientific Content - Overall
Overall, I am satisfied with the scientific content. 4.7
What kinds of sessions would you like to see included at future conferences?
I would like to hear in detail about the molecular mechanisms responsible for the transmission of lysophospholipid signals.
Round table discussion. Instead of "meet the expert", which does not work.
Molecular mechanisms of immune cell trafficking
New candidates (under clinical or preclincal stage)for disease therapy
sphingolipid
Number of Short talk from poster session should be more.
Wider topics on bioactive lipids are welcome
lipid mediator in model animals including zebrafish
New techniques to analyze lysophospholipids and its signaling
cutting edge sections - not the same people who made historic contributions. There seems to be a lot of inbreeding in this area and organizers behind the sceneswho have an unofficial role in perpetuating talks that are not necessarily cutting edge.
Same as present conference and even more time for presentations selected from trainees.
lysophospholipid
some new finding of lipids research in cancer
Section 2 - Management
Program Management & Organization
How satisfied were you with the coordination and organization of the scientific program? 4.6
Lysophospholipid and Other Related Mediators-From Bench to Clinic http://www.planion.com/Planion.Evals/ZZHWPBUU4Z?ACCOUNT=...
1 of 4 10/25/2013 4:19 PM
How satisfied were you the representation of international scientists in this field participating? 4.6
How satisfied were you with the conference materials provided? 4.4
Did you feel the length of conference sessions were too long, just about right, or too short? 2.4
(3=Too long; 2= Just about right; 1=Too short)
Logistics Management & Organization
How satisfied were you with the registration and abstract submission process? 4.4
How satisfied were you with the information found on the FASEB SRC website and from emails sent by the FASEB SRC Office? 4.2
Overall Management & Organization
The conference was well organized. 4.7
Conference onsite staff member was helpful and courteous. 4.7
Overall, I was satisfied with the conference facilities. 4.7
Where would you like to see future SRCs take place?
Europe (Great Britain, Italy etc.)
Banff
Puerto RicoSanta FeBanff
Canada
Convenient travel is important. Niseko location was not ideal.
North America
Alberta, Canada
no
France
Honolulu,USA
Australia
Singapore, Italy, California, Las Vegas
Other places than USA.
Sydney (Australia), Vancouver (Canada)
Africa, south America, Hawaii
Canada, Italy (Europe)
Canada
banff
more sites in Asia or Europe
Canada
Fukuoka, Japan
Europe
Hawaii
BANF
The place that is near to the station.
Europe
USA
Which months are more convenient for you to attend a conference?
June - August: 38 (73.1%)
September - November: 7 (13.5%)
December - February: 6 (11.5%)
March - May: 1 (1.9%)
Overall, how would you rate the FASEB SRC Staffs' professionalism and responsiveness to your questions and concerns? 4.6
Lysophospholipid and Other Related Mediators-From Bench to Clinic http://www.planion.com/Planion.Evals/ZZHWPBUU4Z?ACCOUNT=...
2 of 4 10/25/2013 4:19 PM
Comments:
On site assistance and preparation were very good.I would like to be informed about the schedule more earlier.
Website was not functioning properly, and hence, necessary information could not be obtained prior to the meeting.
Clay was superb.
Clay was an excellent representative of FASEB, provided good information and support for all attendees. He was personable and never failed to be courteous andhelpful.
Section 3 - General Information
Approximately how many conferences of this type do you attend annually?
1-2 per year: 36 (62.1%)
3-4 per year: 14 (24.1%)
5-6 per year: 1 (1.7%)
More than 6 per year: 2 (3.4%)
Don't usually attend conferences: 5 (8.6%)
Do you plan to attend this conference again in 2 or 3 years?
Yes: 56 (96.6%)
No: 2 (3.4%)
Would you recommend this conference to others?
Yes: 55 (93.2%)
No: 0 (0%)
Not Sure: 3 (5.1%)
No response: 1 (1.7%)
How would you rate this conference compared to otherconferences of this type that you have attended? 4.5
How did you learn of this conference?
Co-Worker: 23 (39.7%)
By Invitation: 18 (31%)
FASEB Mailings: 5 (8.6%)
Internet: 5 (8.6%)
FASEB Emails: 4 (6.9%)
Other: 3 (5.2%)
FASEB Journal: 0 (0%)
ExperimentalBiology/Neuroscience/Cell
Biology:0 (0%)
If other, please specify:
Professor: 1 (25%) ORGANIZER: 1 (25%)
I regularlyattend
thisconferenceafter I had
beeninvited:
1 (25%) From labmembers: 1 (25%)
Please indicate your age group:
20's: 4 (6.8%)
30's: 13 (22%)
40's: 18 (30.5%)
50's: 16 (27.1%)
60's: 7 (11.9%)
70's: 1 (1.7%)
In what ways could this conference be improved?
Speakers should be cut off within 1 minute of exceeding their time so that questions can be asked.
Just a small thing: in the mtg booklet, put the names of the rooms where events take place. Later during the mtg you already know where things are, but the firstday or two it's nice to know.
Provide electronic abstracts.Obtain and provide reprints of posters and presentations to attendees after the conference.
By reducing the length of the evening sessions, that were less participated in terms of discussion, likely because everyone was tired.
its quite good already, maybe travel awards for students and postdocs would help
The site is not readily accessible.
this site was difficult to get to
Provide list of attendees before the start of the conference. It would be nice to know which colleagues to expect to see.
Conference fee (2000 US$) of this SRC was too high. Fee should be around 1000 $ or less. For this, luxury hotels in the best season should not been chosen as theconference place.
There were trouble with PC connections. I would like to improve this not to waste time.
A special issue of publication will be helpful
Meet the expert could be a little more formalised by asking delegates to indicate prior to the meeting their wish to meet a particular expert. This can then be formallyscheduled
better speakers, organization by top scientists
There is little need for improvement since this is my favorite conference.
Lysophospholipid and Other Related Mediators-From Bench to Clinic http://www.planion.com/Planion.Evals/ZZHWPBUU4Z?ACCOUNT=...
3 of 4 10/25/2013 4:19 PM
it would be appreciated if you could share us abstract before the conference
sound-equipment and discussion time
The location was a bit pricy.
To invite new scientists into this field.
Lysophospholipid and Other Related Mediators-From Bench to Clinic http://www.planion.com/Planion.Evals/ZZHWPBUU4Z?ACCOUNT=...
4 of 4 10/25/2013 4:19 PM
FINAL REPORT FASEB SCIENCE RESEARCH CONFERENCE, NISEKO, JAPAN
Lysophospholipid and Other Related Mediators – From Bench to Clinic August 4-9, 2013
Organizers: Yasuyuki Igarashi Junken Aoki Takehiko Yokomizo Akio Kihara The 2013 meeting “Lysophospholipid and Other Related Mediators – From Bench to Clinic” was held at Hilton Niseko Village, NIseko, Hokkaido, Japan, from August 4-9th, 2013. The study of lysophospholipid mediators such as sphingosine 1-phosphate, lysophosphatidic acid, and other related mediators such as prostaglandins is of considerable intrinsic interest because of its importance to human health. This meeting was unique in its emphasis on integrating knowledge derived from molecular mechanistic approaches together with applied research for drug development. Internationally renowned scientists from Japan and abroad chaired the sessions and spoke at the conference, that was attended by trainees as well as junior and senior scientists. In total, there were 35 invited speakers (including the organizers and Keynote speaker) and 95 other attendees at this meeting. Our meeting began on Sunday evening with two 45-min keynote addresses by Dr. Gabor Tigyi from University of Tennessee and Dr. Jason Cyster from University of California. During the next 4 days we heard full-length (30 min) talks from 32 invited speakers in 9 formal sessions arranged by topic. Five of the invited speakers were women, and three of the eighteen session chairs were women. In our planning of the sessions we deliberately left time for up to 3 short talks in each sessions to cover late-breaking research, especially from junior investigators. Therefore, 20 additional abstracts were selected for 15-minute presentations in the nine formal sessions. Overall, 32% of the short talk was selected from submitted abstracts for poster presentation. The nine major sessions and keynote address covered the breadth of recent development of S1P and LPA and other related lipid mediators as well as new technologies in lipid study. We avoided the separation of S1P and LPA studies, therefore in the same sessions the two topics are intentionally presented and discussed simultaneously. The formal sessions were entitled: 1) Fundamental aspects of lysophospholipid mediators (1); 2) Fundamental aspects of lysophospholipid mediators (II); 3) Fundamental aspects of lysophospholipid mediators (III); 4) Fundamental aspects of lysophospholipid mediators (IV); 5) Fundamental aspects of lysophospholipid mediators (V); 6) Pathology of lysophospholipid mediators -Cancer-; 7) Pathophysiology of lysophospholipid mediators -Circulation and vasculature-; 8) Pathophysiology of lysophospholipid mediators -Immunity and inflammation-; 9) New technology in lysophospholipid study. Most of the sessions were held in the morning and evening with the afternoons free for “Meet the Expert”, informal discussions and viewing of poster sessions. Two 2-hour poster sessions were also held in which 60 posters were displayed and presented. Most of poster presenters are graduate students, post-doctoral fellows or junior faculties. The intimate and informal setting of the meeting allowed for high quality interactions as indicated by vigourous discussions during the question periods after talks in the main sessions, and continuing through the meals and free times. The poster sessions were in the afternoons. They were very well attended and provided a great setting for discussions based on data presented at the poster sessions. Furthermore, we held the “Meet the Expert” sessions on Monday and Wednesday after the poster sessions to provide young scientists to opportunity to talk with world-renowned experts. Total 18 experts participated in the “Meet the Expert”.
On the Thursday afternoon we offered optional excursion into the malt whisky distilleries of Nikka Whisky, the famous Japanese whisky maker, at Yoichi. About 40 people attended the excursion and enjoyed visiting the factory, purchasing bottles of whisky as a souvenir and tasting whisky. Funding to support this meeting was obtained from a number of sources including the FASEB Science Research Conferences, Amino Up Chemical, Avanti, Earth Chemical, Food Chemicals, Hamanaka Dermatological Clinic, Kao, LS Research Committee, Mitsubishi Tanabe Pharma, Nissei Bio, Ono Pharmaceuticals, Shionogi, Taisho Parmaceutical, Unitika and Universite Laval. Funds were mainly used for reimbursement of the registration fee of the speakers and international attendees and Poster Prize. After dinner on Thursday and before Session 8, the organizers planned a special concert of Japanese traditional drum, called taiko. Attendees enjoyed the stunning performance by local taiko players. We held the business meeting after Session 7 right before lunch. Four young scientists, two were men and the others were women, were awarded the Poster Prizes. Among them, one, Dr. Asuka Inone of Tohoku University, also received the honor of Biochemical Journal Award. We elected Dr. David Brindley, a well-known and highly respected senior scientist from University of Alberta, for the organizer of the next 2015 meeting. The next meeting will held at Banff, Canada. Banff is located in Canada’s first National Park and is UNESCO World Heritage Site. We also elected Dr. Nigel Pyne and Dr. Susan Pyne for the organizer of 2017 meeting. The organizers received positive feedback from numerous attendees such as high quality of presentations, active discussion and great location and meals. Therefore, the organizers felt this meeting was a tremendous success. Yasuyuki Igarashi, Ph.D. Lead Organizer, 2013 Lysophospholipid and Other Related Mediators – From Bench to Clinic
Year# of
Applicants# of
Participants Commercial Non-
Commercial Government Total Raised2001 93 82 -$ 28,300.00$ 2003 160 156 2,000.00$ 42,007.40$ 2005 109 107 16,667.15$ -$ 20,000.00$ 36,667.15$ 2007 126 124 33,391.91$ 8,500.00$ 15,500.00$ 57,391.91$ 2009 149 142 37,307.50$ 4,014.00$ -$ 41,321.50$ 2011 120 112 48,182.01$ 12,500.00$ 9,000.00$ 57,182.01$ 2013 134 128 35,829.27$ 7,073.52$ 42,902.79$
ATTENDANCE FUNDING
Comparison of Previous Conferences
$28,300.00$40,007.40
Lysophospholipid and Related Mediators - from Bench to Clinic
Year Name Affiliation Year Name Affiliation2001 Edward Goetzl Univ. of CA, San Francisco 2013 Yasuyuki Igarashi Hokkaido University
Timothy Hla Univ. of Connecticut Hlth. Ctr. Junken Aoki Tohoku UniversityGabor Tigyi Univ. of Tennessee, Memphis Takehiko Yokomizo Kyushu University
Akio Kihara Hokkaido University2003 Gabor Tigyi Univ. of Tennessee, Memphis
Timothy Hla Univ. of Connecticut Hlth. Ctr.Jerold J.M. Chun Merck Res. Labs., San Diego
2005 Gordon Mills MD Anderson Cancer CenterKevin Lynch Univ. of VirginiaAndrew Morris Univ. of NC, Chapel HillYasuyuki Igarashi Hokkaido Univ.Wouter Moolenaar The Netherlands Cancer Inst.
2007 Sarah Spiegel Virginia Commonwealth Univ. School of MedicineAndrew Morris Univ. of NC, Chapel HillTimothy Hla Univ. of Connecticut Hlth. Ctr.Junken Aoki Univ. of Tokyo
2009 Jerald Chun The Scripps Research InstituteTimothy Hla Univ. of Connecticut Hlth. Ctr.Takao Shimizu Univ. of Tokyo Faculty of Medicine
2011 Julie D. Saba Children’s Hospital Oakland Research InstitutePaola Bruni University of FlorenceGabor Joseph Tigyi Univ. Tennessee
Lysophospholipid and Related Mediators - from Bench to ClinicPast Conference Organizers
December 5, 2011 Dr. Yasuyuki Igarashi Hokkaido University Frontier Research Center for Post-genome Science and Technology Faculty of Advanced Life Science 11-Jou Nishi, Kita, Kita-ku, Sapporo Hokkaido, 001-0021 Japan Re Proposal #: 13-15 Dear Dr. Igarashi: We would like to thank you for submitting a proposal for the 2013 FASEB Summer Research Conference series. After careful consideration by the Advisory Committee, the proposal entitled, "Lysophospholipid and Other Related Mediators - From Bench to Clinic" has been tentatively approved. The committee would like you to respond by Thursday, December 15, 2011 to the following comments/concerns before they will fully approve the proposal:
• The committee requests a more detailed plan for the Meet the Expert session and poster sessions. Please note that the “Meet the Expert” session is a time for attendees (especially students/junior investigators) to meet and network with the “experts” of your program.
• The committee requests that you specify the new speakers in your
proposed program. Please also make an effort to confirm all session chairs.
• After reviewing your proposed program, the committee also requests
that you increase the representation of women, junior investigators, and minorities. The committee requests that you make every effort to include young investigators (poster presentation or a short talk) as early as possible within the conference agenda. This will have an enormous impact on one’s experience at the conference. This will also allow other participants to learn early on about their work and will then greatly increase interaction.
Dr. Igarashi Page 2 We will soon begin the process of developing the conference schedule and will let you know the location and date of your conference as soon as this has been decided. Please keep in mind, location and date preferences are not guaranteed however we do our best to give you your first choice. In February, an Organizer Manual will be posted at our website (www.faseb.org/SRC) to assist you in your conference planning efforts. Please be aware that by agreeing to be an Organizer/Co-organizer of a FASEB Summer Research Conference, that should you decide to cancel the conference for any reason, you will be held responsible for any fees related to the cancellation (i.e., fees charged by the host location). The Summer Research Conferences have been very successful over the years due to the commitment and dedication of the Organizers. On behalf of the Federation and the Summer Research Conferences Advisory Committee, your efforts in contributing to the success of the program are sincerely appreciated. A copy of this letter has also been sent to your co-organizer(s). Please do not hesitate to contact the SRC office by telephone at (301) 634-7010 or via the emails listed below with any questions. We look forward to working with you on this project over the next few years. Sincerely,
Jessica Lyons Conference Manager FASEB Summer Research Conferences [email protected]
Emily Benson Conference Manager FASEB Summer Research Conferences [email protected]
Robin Crawford Conference Manager FASEB Summer Research Conferences [email protected]
The committee requests a more detailed plan for the Meet the Expert session and poster
sessions. Please note that the “Meet the Expert” session is a time for attendees
(especially students/junior investigators) to meet and network with the “experts” of
your program.
Answer: We are planning to hold poster sessions from 15:00-17:00 on day 2 and 3
(Poster session 1) and on day 4 and 5 (Poster session 2) and the “Meet the Expert”
session from 21:00-22:00 on day 2 and 3 while drinking.
The committee requests that you specify the new speakers in your proposed program.
Please also make an effort to confirm all session chairs.
Answer: I have updated the proposed program by specifying the new speakers. We
confirmed the attendance of all session chairs and marked “C” in the updated program.
After reviewing your proposed program, the committee also requests that you increase
the representation of women, junior investigators, and minorities.
Answer: We will make an effort to increase those participants by advertising to choose
them preferentially as short talks from the abstracts submitted during registration.
1
Lyons, Jessica
From: Akio Kihara [[email protected]]Sent: Monday, December 19, 2011 12:46 AMTo: Lyons, JessicaCc: '[email protected]'; '[email protected]'; '[email protected]
u.ac.jp'Subject: Re: 2013 FASEB Summer Research ConferencesAttachments: Proposal Guidelines Lysophospholipid-3.pdf; ATT00001.txt
Dear Jessica, As recommended, we have changed the “Meet the Expert” sessions to be held after lunch on day 2 and 3. Regarding woman speakers, we added Dr. Noriko Takuwa in the updated program. In addition, we have corrected the mistake of not marking Dr. Diana Escalante‐Alcalde as “W”. Now 11 speakers are listed. I have attached to this e‐mail the updated program for your consideration. Sincerely, Akio
Summer 2011 Dear Colleague, We invite you to submit a proposal for a future FASEB Summer Research Conference (SRC). Since 1982, FASEB has worked hand-in-hand with scientists to organize conferences for experimental biologists. The conferences are divided up into small groups, who meet intimately and without distractions to explore new approaches to research areas undergoing rapid scientific change. FASEB supports over 35 SRCs each year. Domestic venues are located in Vermont, Colorado and Arizona and our international venues are in Italy, Japan, Australia, Denmark and this year in Greece! Additionally, we welcome new site suggestions that would be conducive to our group requirements. Please review the attached information and feel free to contact the SRC Office should you have any questions or need guidance in preparing your proposal. We look forward to welcoming you and your conference into the FASEB summer conference series. Sincerely, The FASEB SRC Team: Marcella Jackson, Director ([email protected]) Jessica Lyons, Conference Coordinator ([email protected]) Emily Benson, Conference Assistant ([email protected]) Rachel Roberts, Administrative Assistant ([email protected]) Main Number: 301-634-7010 Fax Number: 301-634-7007
FASEB SRC Proposal Instructions Attached are the instructions and requirements for submitting a FASEB SRC proposal. Please complete sections 1-6 before submitting your information. All proposals need to be submitted in full by Friday, September 23, 2011 in order to be considered for the 2013 SRC series. Proposals will be reviewed by the FASEB Summer Research Conferences Advisory Committee in early November. By November 22, 2011, you will receive a letter with the committee’s decision on your submitted proposal. By the end of January 2012 you will receive a second letter which will indicate the location and date for your conference as well as the name of the Conference Manager from the FASEB SRC Team. Once your conference is approved you will be assigned a conference manager form the FASEB SRC Team who will provide you with detailed instructions on fund raising, program management and timelines to help make your planning process successful and seamless.
Section 1: Organizer Responsibilities: By submitting a FASEB Summer Research Conference proposal for consideration by the FASEB SRC Advisory Committee, the organizer (s) accepts the responsibility for producing a successful conference. Such responsibilities include:
1. Anything related to the scientific portion of your conference. You will need to provide the conference title and topics. The conference title and topics should be timely and attractive. 2. Attendance to your conference is expected to be no less than 100 participants. 3. All fund raising efforts are the responsibility of the organizers with support and guidance by the FASEB SRC Staff. FASEB will provide $10,000 for each conference to help defray a portion of travel and registration costs for speakers. 4. Contacting all speakers and session chairs to invite and confirm their participation. Speakers should be informed that their expenses will be reimbursed after the conference and only to the extent that funds are available. We recommend you do not commitment to a speaker a specific amount of funds prior to the conference. (Note: Invited speakers and session chairs are required to remain at the conference for a minimum of three full days and three full nights in order to be eligible for reimbursement of any conference related expenses.)
5. Reviewing and approving the submitted attendee applications.
6. Including a “Meet the Expert” session in your program. This session is aimed at encouraging the younger investigators an opportunity to network with the more established and senior PIs in your field. 7. Providing a final conference program to your Conference Manager three weeks prior to the conference. The program will include the speaker abstracts (in presentation order), poster abstracts, and a poster listing of the submitted abstracts. The Conference Manager will prepare the cover for the program, the participant list and have the final packet of materials reproduced and shipped to the venue. 8. Constant communication with your Conference Manager. By doing so, this will eliminate any miscommunication or understanding of the policies and procedures that will needed to be followed.
Section 2: Conference Title & Organizer Information: Please insert the title of the conference as you would like it to be advertised in future publications. List the organizer(s) complete contact information and attach a brief CVs (maximum 3 pages) in NIH format for each. Title of Conference: ___________________________________________________________ Organizer & Co-Organizer Information: Organizer 1: ________________________________________Title: ____________________ Affiliation: ___________________________________________________________________ Full Address: ________________________________________________________________ ___________________________________________________________________________ Phone: _______________________ Email: ________________________________________ Organizer 2: ________________________________________Title: ____________________ Affiliation: ___________________________________________________________________ Full Address: ________________________________________________________________ ___________________________________________________________________________ Phone: _______________________ Email: ________________________________________ Organizer 3: ________________________________________Title: ____________________ Affiliation: ___________________________________________________________________ Full Address: ________________________________________________________________ ___________________________________________________________________________ Phone: _______________________ Email: ________________________________________ Organizer 4: ________________________________________Title: ____________________ Affiliation: ___________________________________________________________________ Full Address: ________________________________________________________________ ___________________________________________________________________________ Phone: _______________________ Email: ________________________________________
Section 3: Program Submission Requirements & Outline:
Please insert program details in day order as requested below. Session titles should be listed with session chairs and affiliations. Indicate the proposed tentative talk titles within each session and list up to at least 4 speakers per session (not including short talks selected from submitted abstracts). Please remember to also include the required “Meet the Expert” session. The FASEB SRC Advisory Committee requires all session chairs to be confirmed before the submission of the application. Be sure to indicate with a "C" if the session chair is confirmed, indicate with a “CS” if the speaker is confirmed, indicate with a "W" which session chairs and speakers are women, indicate with an "M" which session chairs and speakers are of a minority group and indicate with the word “NEW” which session chairs and speakers are new to the program. (Note: The committee defines new speakers as one that has NOT spoken at the last two (2) conferences.) Day One (Sunday): Afternoon: Conference Registration Evening: FASEB SRC Welcome Reception & Dinner Keynote Speaker (optional): Name: ______________________ Affiliation: ____________________ Tentative Title of Talk: ______________________________ Day Two Session 1 (Monday AM): Title of Session: ____________________________ Session Chair & Affiliation: ____________________________________ Speaker 1: ________________________________ Affiliation: _____________________________ Tentative Title of Talk: ________________________ Speaker 2: ________________________________ Affiliation: _____________________________ Tentative Title of Talk: ________________________ Speaker 3: ________________________________ Affiliation: _____________________________ Tentative Title of Talk: ________________________ Speaker 4: ________________________________ Affiliation: _____________________________ Tentative Title of Talk: ________________________ Number of short talks selected from abstracts: _____ Session 2 (Monday PM): Title of Session: ____________________________
Session Chair & Affiliation: ____________________________________ Speaker 1: ________________________________ Affiliation: _____________________________ Tentative Title of Talk: ________________________ Speaker 2: ________________________________ Affiliation: _____________________________ Tentative Title of Talk: ________________________ Speaker 3: ________________________________ Affiliation: _____________________________ Tentative Title of Talk: ________________________ Speaker 4: ________________________________ Affiliation: _____________________________ Tentative Title of Talk: ________________________ Number of short talks selected from abstracts: _____ Day Three Session 3 (Tuesday AM): Title of Session: ____________________________ Session Chair & Affiliation: ____________________________________ Speaker 1: ________________________________ Affiliation: _____________________________ Tentative Title of Talk: ________________________ Speaker 2: ________________________________ Affiliation: _____________________________ Tentative Title of Talk: ________________________ Speaker 3: ________________________________ Affiliation: _____________________________ Tentative Title of Talk: ________________________ Speaker 4: ________________________________ Affiliation: _____________________________ Tentative Title of Talk: ________________________ Number of short talks selected from abstracts: _____ Session 4 (Tuesday PM): Title of Session: ____________________________ Session Chair & Affiliation: ____________________________________ Speaker 1: ________________________________
Affiliation: _____________________________ Tentative Title of Talk: ________________________ Speaker 2: ________________________________ Affiliation: _____________________________ Tentative Title of Talk: ________________________ Speaker 3: ________________________________ Affiliation: _____________________________ Tentative Title of Talk: ________________________ Speaker 4: ________________________________ Affiliation: _____________________________ Tentative Title of Talk: ________________________ Number of short talks selected from abstracts: _____ Day Four Session 5 (Wednesday AM): Title of Session: ____________________________ Session Chair & Affiliation: ____________________________________ Speaker 1: ________________________________ Affiliation: _____________________________ Tentative Title of Talk: ________________________ Speaker 2: ________________________________ Affiliation: _____________________________ Tentative Title of Talk: ________________________ Speaker 3: ________________________________ Affiliation: _____________________________ Tentative Title of Talk: ________________________ Speaker 4: ________________________________ Affiliation: _____________________________ Tentative Title of Talk: ________________________ Number of short talks selected from abstracts: _____ Session 6 (Wednesday PM): Title of Session: ____________________________ Session Chair & Affiliation: ____________________________________ Speaker 1: ________________________________ Affiliation: _____________________________ Tentative Title of Talk: ________________________
Speaker 2: ________________________________ Affiliation: _____________________________ Tentative Title of Talk: ________________________ Speaker 3: ________________________________ Affiliation: _____________________________ Tentative Title of Talk: ________________________ Speaker 4: ________________________________ Affiliation: _____________________________ Tentative Title of Talk: ________________________ Number of short talks selected from abstracts: _____ Day Five Session 7 (Thursday AM): Title of Session: ____________________________ Session Chair & Affiliation: ____________________________________ Speaker 1: ________________________________ Affiliation: _____________________________ Tentative Title of Talk: ________________________ Speaker 2: ________________________________ Affiliation: _____________________________ Tentative Title of Talk: ________________________ Speaker 3: ________________________________ Affiliation: _____________________________ Tentative Title of Talk: ________________________ Speaker 4: ________________________________ Affiliation: _____________________________ Tentative Title of Talk: ________________________ Number of short talks selected from abstracts: _____ Session 8 (Thursday PM): Title of Session: ____________________________ Session Chair & Affiliation: ____________________________________ Speaker 1: ________________________________ Affiliation: _____________________________ Tentative Title of Talk: ________________________ Speaker 2: ________________________________ Affiliation: _____________________________ Tentative Title of Talk: ________________________
Speaker 3: ________________________________ Affiliation: _____________________________ Tentative Title of Talk: ________________________ Speaker 4: ________________________________ Affiliation: _____________________________ Tentative Title of Talk: ________________________ Number of short talks selected from abstracts: _____ Day Six Session 9 (Friday AM - Optional): Title of Session: ____________________________ Session Chair & Affiliation: ____________________________________ Speaker 1: ________________________________ Affiliation: _____________________________ Tentative Title of Talk: ________________________ Speaker 2: ________________________________ Affiliation: _____________________________ Tentative Title of Talk: ________________________ Speaker 3: ________________________________ Affiliation: _____________________________ Tentative Title of Talk: ________________________ Speaker 4: ________________________________ Affiliation: _____________________________ Tentative Title of Talk: ________________________ Number of short talks selected from abstracts: _____
End of Conference
Section 4: Content Assessment: Please complete the grid below which will assist the FASEB SRC Advisory Committee in assessing the requirements of the proposal. Positive reviews are given to proposals with confirmation of session chairs and invited speakers, new speakers to the program, a good representation of women, and a sufficient number of short talks from junior level investigators. Indicate the number of session chairs that have confirmed their participation: Indicated the number of women included with the entire program: Indicate the number of session chairs/speakers of a minority group: Indicate the number of “new” speakers to the conference: Indicate the number of speakers that have confirmed their participation in the conference: Indicated the number of talks set aside for junior level investigators to present their work: Indicated the number of poster sessions that will be organized: Please provide a brief description of the how the poster sessions will be organized: Indicate (if known) if there is a potential of a conflict with any other FASEB SRC or any other society or industry meeting. If yes, please explain the conflict in detail.
Section 5: Scheduling & Location Preferences:
Select three (3) choices of dates from early June through the middle of October the year you wish to hold the conference. Conferences begin on a Sunday and conclude on a Friday. Week 1: ___________________ Week 2: ___________________ Week 3: _______________ Check at least three (3) different venues for consideration. The venue checked in column “1” should be the most preferred. (Note: We will do our best to give you your first choice but it cannot be guaranteed.)
Traditional Venues: 1 2 3 Snowmass Village, Colorado Steamboat Springs, Colorado Saxtons River, Vermont Barga (Lucca), Italy (August – mid October only)
Other Possible Venues: 1 2 3 Arizona (Tucson or Phoenix area) California (Palm Springs area) Montana (Big Sky) New York (Niagara Falls) Bahamas (Nassau)
Section 6: Justification:
The SRC Advisory Committee requires all proposals to include answers to the following eleven (11) questions. In a separate Microsoft word document, answer each individual question accordingly. Once completed, name the document the title of your conference and attach this file to your email when submitting the final proposal. 1. Explain why this topic is of high current interest to the scientific community. 2. Is this a rapidly growing field? 3. Has there been previous conferences of this topic? If so, where and when were the conferences held? How many participants attended? (Additionally, consider whether or not another similar conference/meeting is scheduled that might cause a conflict). 4. How many participants do you expect to attend the conference? 5. What is the percentage of women have participated in this conference in the past (if it has been previously held)? 6. How will you recruit young investigators to attend and participate in the conference? 7. How will you recruit and select new speakers? 8. From what sources and resources will you use to solicit funds for the conference? (Provide specifics). 9. What societies and disciplines will you attract to attend the conference? (Provide specifics). 10. Where will you advertise the conference? What types of media will you use to advertise your conference? (Provide specifics). 11. Are you planning on submitting a similar application to another organization for additional funding and sponsorship? If yes, please clarify.
Section 7: Submitting Your Proposal:
Please read the directions below for submitting your proposal. Feel free to contact the SRC Office should you have any questions or need guidance in submitting your proposal. Instructions for submitting your proposal: 1. Print or save a copy of this form for your own records. 2. Click the "Submit By Email" button below. In the pop-up box, select the option that best describes how you send email. 3. Enter the title of your conference in the message line. 4. Attach the following items to your e-mail:
• The file saved to your personal computer with the answers to the eleven questions in Section 6: Justification
• CVs (in NIH Format) for all Organizers and Co-Organizers (maximum of 3 pages). 5. After you have completed the steps above, click “Submit by Email” button to send your proposal.
Thank you in advance for your proposal submission! We look forward to helping you plan a successful conference.
For more information, please contact: Marcella Jackson, Director FASEB Summer Research Conferences 301-634-7012, [email protected] Jessica Lyons, Conference Coordinator FASEB Summer Research Conferences 301-634-7018, [email protected] Emily Benson, Conference Assistant FASEB Summer Research Conferences 301-634-7094, [email protected] Rachel Roberts, Administrative Assistant FASEB Summer Research Conferences 301-634-7206, [email protected]
1
Lyons, Jessica
From: Akio Kihara [[email protected]]Sent: Wednesday, December 21, 2011 7:17 PMTo: Lyons, JessicaCc: '[email protected]'; '[email protected]'; '[email protected]
u.ac.jp'Subject: Re: 2013 FASEB Summer Research Conferences
Dear Jessica, The "Meet the Expert" sessions will be held at 13:00‐15:00 on day 2 and 3 at one conference room where three senior experts will wait for free scientific talk and/or discussion with young scientists. Thank you. Akio ‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ ‐‐‐‐‐‐‐‐‐‐‐ Akio Kihara, PhD. Laboratory of Biochemistry Faculty of Pharmaceutical Sciences, Hokkaido University Kita 12‐jo, Nishi 6‐chome, Kita‐ku, Sapporo 060‐0812, Japan Phone: 81‐11‐706‐3754, Fax:81‐11‐706‐4900 e‐mail: [email protected] On 2011/12/22, at 0:53, Lyons, Jessica wrote: > Dear Dr. Kihara, > > Can you give more detail about how you will run the Meet the Expert > Session? > > Thank you, > Jessica > > > ‐‐‐‐‐Original Message‐‐‐‐‐ > From: Akio Kihara [mailto:[email protected]] > Sent: Monday, December 19, 2011 12:46 AM > To: Lyons, Jessica > Cc: '[email protected]'; '[email protected]'; > '[email protected]‐u.ac.jp' > Subject: Re: 2013 FASEB Summer Research Conferences > > Dear Jessica, > > As recommended, we have changed the "Meet the Expert" sessions to be > held after lunch on day 2 and 3. > > Regarding woman speakers, we added Dr. Noriko Takuwa in the updated > program. In addition, we have corrected the mistake of not marking Dr. > Diana Escalante‐Alcalde as "W". Now 11 speakers are listed.
2
> > I have attached to this e‐mail the updated program for your > consideration. > > Sincerely, > > Akio >